


```
=>
Uploading C:\Program Files\Stnexp\Queries\10590813-final.str
```



chain nodes :

6 7 8 9 10

ring nodes :

1 2 3 4 5

chain bonds :

1-8 3-6 6-7 8-9 8-10

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 1-8 2-3 3-4 3-6 4-5 6-7 8-9 8-10

isolated ring systems :


containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:Atom

L1 STRUCTURE UPLOADED

```
=>
Uploading C:\Program Files\Stnexp\Queries\10590813-intermediate.str
```



chain nodes :

7 8 9 10
ring nodes :
1 2 3 4 5
chain bonds :
3-7 5-8 8-9 8-10
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 3-7 4-5 5-8 8-9 8-10
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

L5 STRUCTURE UPLOADED

=> d his

FILE 'REGISTRY' ENTERED AT 16:12:26 ON 08 JUN 2009
L1 STRUCTURE UPLOADED
L3 514 S L1 SSS FULL


FILE 'CAPLUS' ENTERED AT 16:13:03 ON 08 JUN 2009
L4 23 S L3

FILE 'REGISTRY' ENTERED AT 16:14:10 ON 08 JUN 2009
L5 STRUCTURE UPLOADED
L7 9355 S L5 SSS FULL


FILE 'CAPLUS' ENTERED AT 16:14:33 ON 08 JUN 2009
L8 14468 S L7
L9 11 S L8 AND L4
L11 1 S US200!-590813/APPS
L12 1 S L9 AND L11
L13 10 S L9 NOT L11

FILE 'REGISTRY' ENTERED AT 16:15:55 ON 08 JUN 2009

=> d l1
L1 HAS NO ANSWERS
L1 STR



=> d 15
L5 HAS NO ANSWERS
L5 STR



=> fil caplus

=> d 112

√L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN				
PA	Applied Research Systems Ars Holding N. V., Neth. Antilles			
	PATENT NO.	KIND	DATE	√APPLICATION NO.
PI	WO 2005082848	A2	20050909	WO 2005-EP50852
	WO 2005082848	A3	20051201	
	AU 2005217153	A1	20050909	AU 2005-217153
	CA 2554767	A1	20050909	CA 2005-2554767
	EP 1725526	A2	20061129	EP 2005-708062
	EP 1725526	B1	20071212	
	CN 1946686	A	20070411	CN 2005-80012856
	BR 2005008059	A	20070717	BR 2005-8059
	JP 2007524702	T	20070830	JP 2007-500229
	AT 380792	T	20071215	AT 2005-708062
	ES 2296137	T3	20080416	ES 2005-708062
	MX 2006009776	A	20061030	MX 2006-9776

KR 2006124775	A	20061205	KR 2006-719448	20060921
US 20070197794	A1	20070823	US 2007-590813	20070110 <--
PRAI EP 2004-100773	A	20040226		
WO 2005-EP50852	W	20050228		

=> d 113 tot bib abs hitstr

√L13 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

PA	Enanta Pharmaceuticals, Inc., USA			
	PATENT NO.	KIND	DATE	APPLICATION NO.
PI	-----	-----	-----	-----
PI	WO 2009003009	A1	20081231	WO 2008-US68130
	US 20090004140	A1	20090101	US 2008-145943
	US 20090022689	A1	20090122	US 2008-169906
	US 20090047247	A1	20090219	US 2008-190294
	US 20090053175	A1	20090226	US 2008-196642
	US 20090060874	A1	20090305	US 2008-205052
PRAI	US 2007-946312P	P	√20070626	
	US 2007-950388P	P	20070718	
	US 2007-953351P	P	20070801	
	US 2007-955511P	P	20070813	
	US 2007-957876P	P	20070824	
	US 2007-970126P	P	20070905	
	US 2007-971701P	P	20070912	
	US 2008-60705P	P	20080611	
	US 2008-60708P	P	20080611	
	US 2008-60943P	P	20080612	

√L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

SO Journal of Combinatorial Chemistry (2008), 10(3), 391-400

L13 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:740289 CAPLUS Full-text

DN 141:243336

TI Preparation of pyrrolidin-3-one oximes as oxytocin antagonists

IN Schwarz, Matthias; Jorand-lebrun, Catherine; Valognes, Delphine

PA Applied Research Systems Ars Holding N.V., Neth.

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 1

PA	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	-----	-----	-----	-----	-----
PI	WO 2004076407	A2	20040910	WO 2004-EP50142	20040216
	WO 2004076407	A3	20041021		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2004215661	A1 20040910	AU 2004-215661	20040216
CA 2515546	A1 20040910	CA 2004-2515546	20040216
EP 1597229	A2 20051123	EP 2004-711384	20040216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006519212	T 20060824	JP 2006-502031	20040216
US 20070037806	A1 20070215	US 2005-547032	20050826
NO 2005004442	A 20050926	NO 2005-4442	20050926
PRAI EP 2003-100477	A 20030227		
WO 2004-EP50142	A 20040216		
OS MARPAT 141:243336			
GI			




AB Title compds. I [R1 = H or alkyl; B = COO, CONH and derivs., oxadiazole, thiadiazole, benzimidazole; R2 = H, alkyl, (substituted)aryl, (substituted)heteroaryl, etc.; R3 = aryl or heteroaryl; A = (CH₂)_n; n = 1-3; their geometrical isomers, enantiomers, diastereomers, their mixts. and racemates, and their salts] were prepared as oxytocin receptor antagonists for the prevention and/or treatment of preterm labor, premature birth or dysmenorrhea. Thus, reaction of [(2S,4R)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-4-hydroxypyrrolidin-2-yl]acetic acid (preparation given) with (diazomethyl)trimethylsilane, followed by oxidation and oximation gave the oxime (2S)-II in 94% purity. In an in vitro assay, (2S)-II inhibited the binding of ¹²⁵I-Ornithin Vasoactive to human oxytocin receptor with Ki value of 37 μM.

IT 13726-69-7P, (4R)-1-(tert-Butoxycarbonyl)-4-hydroxy-L-proline
 37813-30-2P 753014-18-5P 753014-26-5P,
 [(2S)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-4-(methoxyimino)pyrrolidin-2-yl]acetic acid 753014-27-6P,
 3-[(2R)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-4-(methoxyimino)pyrrolidin-2-yl]propanoic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of pyrrolidin-3-one oximes as oxytocin


antagonists)
 RN 13726-69-7 CAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) ester,
 (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 37813-30-2 CAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl)
 2-ethyl ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 753014-18-5 CAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-[(1,1-dimethylethyl)dimethylsilyl]oxy-, 1-(1,1-dimethylethyl) 2-ethyl ester,
 (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 753014-26-5 CAPLUS
 CN 2-Pyrrolidineacetic acid, 1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 753014-27-6 CAPLUS

CN 2-Pyrrolidinepropanoic acid, 1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



IT 753014-40-3P, N-(2-Aminophenyl)-3-[(2R)-1-[(1,1'-biphenyl-4-yl)carbonyl]-4-(methoxyimino)pyrrolidin-2-yl]propanamide


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(oxytocin antagonist; preparation of pyrrolidin-3-one oximes as oxytocin antagonists)

RN 753014-40-3 CAPLUS

CN 2-Pyrrolidinepropanamide, N-(2-aminophenyl)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



IT 753014-28-7P, Methyl 2-[(2S)-1-((1,1'-biphenyl)-4-yl)carbonyl]-4-

(methoxyimino)pyrrolidin-2-yl]acetate 753014-30-1P, Methyl
 3-[(2R)-1-[(1,1'-biphenyl-4-yl)carbonyl]-4-(methoxyimino)pyrrolidin-2-
 yl]propanoate 753014-31-2P, Cyclopentyl
 2-[(2S)-1-[(1,1'-biphenyl-4-yl)carbonyl]-4-(methoxyimino)pyrrolidin-2-
 yl]acetate 753014-32-3P, Cyclopentyl
 3-[(2R)-1-[(1,1'-biphenyl-4-yl)carbonyl]-4-(methoxyimino)pyrrolidin-2-
 yl]propanoate 753014-33-4P,
 2-[(2S)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-4-(methoxyimino)pyrrolidin-2-yl]-
 N-((2S)-2-hydroxy-2-phenylethyl)acetamide 753014-34-5P,
 3-[(2R)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-4-(methoxyimino)pyrrolidin-2-yl]-N-
 ((2S)-2-hydroxy-2-phenylethyl)propanamide 753014-35-6P,
 2-[(2S)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-4-(methoxyimino)pyrrolidin-2-
 yl]acetamide 753014-36-7P,
 3-[(2R)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-4-(methoxyimino)pyrrolidin-2-
 yl]propanamide 753014-37-8P,
 (5S)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-5-[2-(morpholin-4-yl)-2-
 oxoethyl]pyrrolidin-3-one O-methyloxime 753014-38-9P,
 (5R)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-5-[3-(morpholin-4-yl)-3-
 oxopropyl]pyrrolidin-3-one O-methyloxime 753014-39-0P,
 N-(2-Aminophenyl)-2-[(2S)-1-[(1,1'-biphenyl-4-yl)carbonyl]-4-
 (methoxyimino)pyrrolidin-2-yl]acetamide 753014-41-4P,
 (5S)-5-(1H-Benzimidazol-2-ylmethyl)-1-[(1,1'-biphenyl-4-
 yl)carbonyl]pyrrolidin-3-one O-methyloxime 753014-42-5P,
 (5R)-5-[2-(1H-Benzimidazol-2-yl)ethyl]-1-[(1,1'-1,1'-biphenyl-4-
 yl)carbonyl]pyrrolidin-3-one O-methyloxime 753014-43-6P,
 (5S)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-5-[(3-methyl-1,2,4-oxadiazol-5-
 yl)methyl]pyrrolidin-3-one O-methyloxime 753014-44-7P,
 (5R)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-5-[2-(3-methyl-1,2,4-oxadiazol-5-
 yl)ethyl]pyrrolidin-3-one O-methyloxime 753014-45-8P,
 (5S)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-5-[[3-(2-hydroxyethyl)-1,2,4-
 oxadiazol-5-yl]methyl]pyrrolidin-3-one O-methyloxime 753014-46-9P
 , (5R)-1-[(1,1'-Biphenyl-4-yl)carbonyl]-5-[2-[3-(2-hydroxyethyl)-1,2,4-
 oxadiazol-5-yl]ethyl]pyrrolidin-3-one O-methyloxime 753014-47-0P
 , (5R)-5-[2-(1H-Benzimidazol-2-yl)ethyl]-1-[(1,1'-biphenyl-4-
 yl)carbonyl]pyrrolidin-3-one O-methyloxime

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(oxytocin antagonist; preparation of pyrrolidin-3-one oximes as oxytocin
 antagonists)

RN 753014-28-7 CAPLUS

CN 2-Pyrrolidineacetic acid, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-4-
 (methoxyimino)-, methyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 753014-30-1 CAPLUS

CN 2-Pyrrolidinepropanoic acid, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, methyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 753014-31-2 CAPLUS

CN 2-Pyrrolidineacetic acid, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, cyclopentyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 753014-32-3 CAPLUS

CN 2-Pyrrolidinepropanoic acid, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, cyclopentyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 753014-33-4 CAPLUS

CN 2-Pyrrolidineacetamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 753014-34-5 CAPLUS

CN 2-Pyrrolidinepropanamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 753014-35-6 CAPLUS

CN 2-Pyrrolidineacetamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 753014-36-7 CAPLUS

CN 2-Pyrrolidinepropanamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-

(methoxyimino)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 753014-37-8 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[2-(4-morpholinyl)-2-oxoethyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 753014-38-9 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-(4-morpholinyl)-3-oxopropyl]-, 3-(O-methyloxime), (5R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 753014-39-0 CAPLUS


CN 2-Pyrrolidineacetamide, N-(2-aminophenyl)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 753014-41-4 CAPLUS
CN 3-Pyrrolidinone, 5-((1H-benzimidazol-2-ylmethyl)-1-((1,1'-biphenyl)-4-ylcarbonyl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 753014-42-5 CAPLUS
CN 3-Pyrrolidinone, 5-((1H-benzimidazol-2-ylmethyl)-1-((1,1'-biphenyl)-4-ylcarbonyl)-, 3-(O-methyloxime), (5R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 753014-43-6 CAPLUS
CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[(3-methyl-1,2,4-

oxadiazol-5-yl)methyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 753014-44-7 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-, 3-(O-methyloxime), (5R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 753014-45-8 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl)methyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 753014-46-9 CAPLUS


CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[2-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]ethyl]-, 3-(O-methyloxime), (5R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 753014-47-0 CAPLUS
CN 3-Pyrrolidinone, 5-[2-(1H-benzimidazol-2-yl)ethyl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-, 3-(O-methyloxime), (5R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 51-35-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolidin-3-one oximes as oxytocin antagonists)
RN 51-35-4 CAPLUS
CN L-Proline, 4-hydroxy-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:41436 CAPLUS Full-text
DN 140:93917



TI Preparation of pyrrolidine derivatives as oxytocin antagonists
 IN Jorand-Lebrun, Catherine; Dorbais, Jerome; Quattropani, Anna; Schwarz,
 Matthias; Valognes, Delphine
 PA Applied Research Systems Ars Holding N.V., Neth. Antilles
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005249	A1	20040115	WO 2003-EP50286	20030704
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2487532	A1	20040115	CA 2003-2487532	20030704
	AU 2003254498	A1	20040123	AU 2003-254498	20030704
	BR 2003012586	A	20050412	BR 2003-12586	20030704
	EP 1532109	A1	20050525	EP 2003-762692	20030704
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1678576	A	20051005	CN 2003-820401	20030704
	CN 1330633	C	20070808		
	JP 2005533828	T	20051110	JP 2004-518783	20030704
	MX 2005000326	A	20050331	MX 2005-326	20050105
	NO 2005000612	A	20050203	NO 2005-612	20050203
	US 20060004020	A1	20060105	US 2005-518543	20050711
	US 7115754	B2	20061003		
	HK 1076107	A1	20071207	HK 2005-110274	20051117
PRAI	EP 2002-100784	A	20020705		
	WO 2003-EP50286	W	20030704		
OS	MARPAT 140:93917				
GI					



AB The title compds. I [R1 = H or alkyl; R2 = H, alkyl, (substituted)aryl, (substituted)heteroaryl, etc.; R3 = aryl or heteroaryl; X = O or (substituted)amino; n = 1-3] were prepared as oxytocin antagonists for the prevention and/or treatment of preterm labor, premature birth or dysmenorrhea. Thus, reaction of 1-tert-butyl-2-Me (2S)-4-(methoxyimino)-1,2-pyrrolidine-dicarboxylate (preparation given) with 2'-methyl[1,1'-biphenyl]-4-carboxylic acid followed by hydrolysis and reduction gave compound II. The latter inhibits oxytocin mediated Ca²⁺-mobilization with IC₅₀ = 0.03 μM. Pharmaceutical compns. containing I are described.


IT 643001-53-0P 643001-56-3P 643001-57-4P
643001-63-2P 643001-64-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrrolidine derivs. as oxytocin antagonists)

RN 643001-53-0 CAPLUS

CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-(hydroxymethyl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 643001-56-3 CAPLUS

CN Acetic acid, 2-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-

pyrrolidinyl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-57-4 CAPLUS

CN Acetic acid, 2-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-63-2 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 643001-64-3 CAPLUS


CN 3-Pyrrolidinone, 5-(aminomethyl)-1-((1,1'-biphenyl)-4-ylcarbonyl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 643001-52-9P 643001-54-1P 643001-55-2P
643001-58-5P 643001-59-6P 643001-60-9P
643001-61-0P 643001-62-1P 643001-65-4P
643001-66-5P 643001-67-6P 643001-68-7P
643001-69-8P 643001-70-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidine derivs. as oxytocin antagonists)
RN 643001-52-9 CAPPLUS
CN 3-Pyrrolidinone, 5-(hydroxymethyl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 643001-54-1 CAPPLUS
CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-(hydroxymethyl)-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 643001-55-2 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-(hydroxymethyl)-, 3-(O-methyloxime), (3E,5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 643001-58-5 CAPLUS

CN Acetamide, 2-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]methoxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-59-6 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-(methoxymethyl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-60-9 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[[(4-methyl-1-piperazinyl)methyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-61-0 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[[(4-methoxyphenyl)amino]methyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-62-1 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[[(2-(1H-pyrazol-1-yl)ethyl)amino]methyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-65-4 CAPLUS

CN Acetamide, N-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-66-5 CAPLUS

CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-(1-piperidinylmethyl)-, 3-(O-methyloxime), (5*S*)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-67-6 CAPLUS

CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-(2-hydroxyethyl)-, 3-(O-methyloxime), (5*S*)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-68-7 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[(4-methyl-1-piperazinyl)methyl]-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 643001-69-8 CAPLUS

CN Carbonic acid, [(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]methyl 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-70-1 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[(carboxyoxy)methyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




IT 13726-69-7 40216-83-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolidine derivs. as oxytocin antagonists)

RN 13726-69-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) ester,
(2S,4R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 40216-83-9 CAPLUS

CN L-Proline, 4-hydroxy-, methyl ester, hydrochloride (1:1), (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT 84348-37-8P 461418-01-9P 461418-05-3P

643001-71-2P 643001-75-6P 643001-76-7P

643001-77-8P 643001-88-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of pyrrolidine derivs. as oxytocin antagonists)

RN 84348-37-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) ester,
(2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 461418-01-9 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 461418-05-3 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 643001-71-2 CAPLUS

CN L-Proline, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-hydroxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 643001-75-6 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[(1,1-dimethylethyl)dimethylsilyloxy]methyl-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 643001-76-7 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[(methylsulfonyloxy)methyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 643001-77-8 CAPLUS

CN L-Proline, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-[(1,1-dimethylethyl)dimethylsilyloxy]-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 643001-88-1 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[2-[(1,1-dimethylethyl)dimethylsilyloxy]ethyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2003:928879 CAPLUS Full-text

DN 140:163606

TI Synthesis and biological activity of novel 1 β -Methylcarbapenems with oxyiminopyrrolidinylamide moiety

AU Lee, Ji Hoon; Lee, Kyung Seok; Kang, Yong Koo; Yoo, Kyung Ho; Shin, Kye Jung; Kim, Dong Chan; Kong, Jae Yang; Lee, Yeonhee; Lee, Sook Ja; Kim, Dong Jin

CS Medicinal Chemistry Research Center, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea

SO Bioorganic & Medicinal Chemistry Letters (2003), 13(24), 4399-4403
CODEN: BMCLE8; ISSN: 0960-894X


PB Elsevier Science B.V.

DT Journal

LA English

OS CASREACT 140:163606

GI



I

AB The synthesis and antibacterial activity of novel 1 β -methylcarbapenems bearing oxyiminopyrrolidinylamide moiety at C-5 position of pyrrolidine are described. Most compds. exhibited comparable antibacterial activity to meropenem against a wide range of Gram-pos. and Gram-neg. organisms including *Pseudomonas aeruginosa* isolates. Of these carbapenems, I showed potent and broad spectrum of antibacterial activity and similar stability to DHP-I to meropenem. Against clin. isolates of 40 Gram-neg. bacterial species including MDR and ESBL-producing strains, the selected carbapenem I possessed excellent in vitro activity except for MDR *P. aeruginosa*, and was comparable in potency to meropenem.

IT 654638-60-5P 654638-87-6P 654638-88-7P
654638-89-8P 654638-90-1P 654638-91-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(synthesis and biol. activity of novel 1 β -Methylcarbapenems with oxyiminopyrrolidinylamide moiety)

RN 654638-60-5 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(3-(hydroxyimino)-1-pyrrolidinyl]carbonyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, (4R,5S,6S)-(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-87-6 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(3-(methoxyimino)-1-pyrrolidinyl]carbonyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, (4R,5S,6S)-(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-88-7 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
 3-[(3S,5S)-5-[[3-(aminomethyl)-4-(hydroxyimino)-1-pyrrolidinyl]carbonyl]-
 3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5S,6S)-
 (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-89-8 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
 3-[(3S,5S)-5-[[3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]carbonyl]-
 3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5S,6S)-
 (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-90-1 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
 3-[(3S,5S)-5-[[3-carboxy-4-(hydroxyimino)-1-pyrrolidinyl]carbonyl]-3-
 pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5S,6S)-
 (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-91-2 CAPLUS
 CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
 3-[(3S,5S)-5-[[3-(ethoxycarbonyl)-4-(hydroxyimino)-1-
 pyrrolidinyl]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-
 methyl-7-oxo-, (4R,5S,6S)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




IT 51-35-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis and biol. activity of novel 1β-Methylcarbapenems with
 oxyiminopyrrolidinylamide moiety)
 RN 51-35-4 CAPLUS
 CN L-Proline, 4-hydroxy-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 126407-76-9P 654638-64-9P 654638-65-0P
 654638-67-2P 654638-68-3P 654638-69-4P
 654638-74-1P 654638-75-2P 654638-76-3P
 654638-77-4P 654638-78-5P 654638-79-6P
 654638-80-9P 654638-81-0P 654638-82-1P
 654638-83-2P 654638-84-3P 654638-85-4P
 654638-86-5P 654638-93-4P 654638-94-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis and biol. activity of novel 1β-Methylcarbapenems with
 oxyiminopyrrolidinylamide moiety)
 RN 126407-76-9 CAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(2-propen-1-yl) ester,
 (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 654638-64-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 2-[(4-methoxyphenyl)methyl] 1-(2-propen-1-yl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 654638-65-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[(methylsulfonyl)oxy]-, 2-[(4-methoxyphenyl)methyl] 1-(2-propen-1-yl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 654638-67-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[3-(hydroxyimino)-1-pyrrolidinyl]carbonyl]-, 2-propen-1-yl ester, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-68-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[(3-(hydroxyimino)-1-pyrrolidinyl)carbonyl]-4-mercaptopro-, 2-propen-1-yl ester, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-69-4 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(3-(hydroxyimino)-1-pyrrolidinyl)carbonyl]-1-[(2-propen-1-yloxy)carbonyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, 2-propen-1-yl ester, (4R,5S,6S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-74-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[(3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl)carbonyl]-, 2-propen-1-yl ester, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-75-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[3-carboxy-4-(hydroxyimino)-1-pyrrolidinyl]carbonyl-, 1-(2-propenyl) ester, (2S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-76-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[3-(ethoxycarbonyl)-4-(hydroxyimino)-1-pyrrolidinyl]carbonyl-, 2-propenyl ester, (2S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-77-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-mercaptop-2-[3-(methoxyimino)-1-pyrrolidinyl]carbonyl-, 2-propen-1-yl ester, (2S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-78-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[3-(aminomethyl)-4-(hydroxyimino)-1-pyrrolidinyl]carbonyl]-4-mercaptopo-, 2-propen-1-yl ester, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-79-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]carbonyl]-4-mercaptopo-, 2-propen-1-yl ester, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-80-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[3-carboxy-4-(hydroxyimino)-1-pyrrolidinyl]carbonyl]-4-mercaptopo-, 1-(2-propenyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-81-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[(3-(ethoxycarbonyl)-4-(hydroxyimino)-1-pyrrolidinyl]carbonyl]-4-mercaptopro-2-propenyl ester, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-82-1 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(3-(methoxyimino)-1-pyrrolidinyl]carbonyl]-1-[(2-propen-1-yloxy)carbonyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, 2-propen-1-yl ester, (4R,5S,6S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 654638-83-2 CAPLUS


CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[(3S,5S)-5-[(3-(aminomethyl)-4-(hydroxyimino)-1-pyrrolidinyl]carbonyl]-1-[(2-propen-1-yloxy)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, 2-propen-1-yl ester, (4R,5S,6S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 654638-84-3 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
3-[(3S,5S)-5-[(3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]carbonyl]-
1-[(2-propen-1-yloxy)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-
hydroxyethyl]-4-methyl-7-oxo-, 2-propen-1-yl ester, (4R,5S,6S)- (CA INDEX
NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 654638-85-4 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
3-[(3S,5S)-1-carboxy-5-[(3-carboxy-4-(hydroxyimino)-1-
pyrrolidinyl]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-
methyl-7-oxo-, 2-(2-propen-1-yl) ester, (4R,5S,6S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 654638-86-5 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
3-[(3S,5S)-1-(ethoxycarbonyl)-5-[(3-(ethoxycarbonyl)-4-(hydroxyimino)-1-pyrrolidinyl]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, 2-propen-1-yl ester, (4R,5S,6S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-93-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[(3-(methoxyimino)-1-pyrrolidinyl]carbonyl]-, 2-propen-1-yl ester, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 654638-94-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[(3-(aminomethyl)-4-(hydroxyimino)-1-pyrrolidinyl]carbonyl]-, 2-propen-1-yl ester, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:977813 CAPLUS Full-text
DN 138:55968
TI Preparation of (biphenylylcarbonyl)(oxadiazolyl or thiadiazolyl)pyrrolidinone oximes as oxytocin receptor antagonists for treatment of preterm labor, premature birth, and dysmenorrhea
IN Schwarz, Matthias; Page, Patrick; Pomel, Vincent; Quattropani, Anna; Thomas, Russell J.
PA Applied Research Systems ARS Holding N.V., Neth. Antilles
SO PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102799	A2	20021227	WO 2002-EP6629	20020614
	WO 2002102799	A3	20030403		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2449578	A1	20021227	CA 2002-2449578	20020614
	AU 2002319237	A1	20030102	AU 2002-319237	20020614
	AU 2002319237	B2	20080103		
	EE 200400022	A	20040415	EE 2004-22	20020614
	BR 2002011030	A	20040622	BR 2002-11030	20020614
	HU 2004000238	A2	20040728	HU 2004-238	20020614
	EP 1444225	A2	20040811	EP 2002-748785	20020614
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004534804	T	20041118	JP 2003-506272	20020614
	CN 1639155	A	20050713	CN 2002-815944	20020614
	ZA 2003009402	A	20041203	ZA 2003-9402	20031203
	NO 2003005399	A	20040217	NO 2003-5399	20031204
	BG 108424	A	20050331	BG 2003-108424	20031208
	IN 2003DN02125	A	20060120	IN 2003-DN2125	20031208
	MX 2003011441	A	20040701	MX 2003-11441	20031210

US	20040220238	A1	20041104	US	2004-480992	20040519
US	7115639	B2	20061003			
US	20060229343	A1	20061012	US	2006-449802	20060609
PRAI	EP 2001-113632	A	20010618			
	WO 2002-EP6629	W	20020614			
	US 2004-480992	A1	20040519			
OS	MARPAT 138:55968					
GI						



AB The present invention is related to the preparation and use of title compds. I [wherein A = CO, CO₂, SO₂, SO₂NH, or CH₂; B = oxadiazole or thiadiazole ring; R₁ = alkyl, alkenyl, alkynyl, (hetero)aryl, or alkyl(hetero)aryl; or OR₁ = heterocyclic ring optionally fused with a (hetero)aryl or cycloalkyl ring; R₂ = (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, (alkyl)heteroaryl, heteroarylalkyl, acyl, etc.; R₃-R₆ = independently H, halo, alkyl, or alkoxy; or geometrical isomers, enantiomers, diastereomers, racemates, or pharmaceutically acceptable salts thereof], as well as pharmaceutical formulations containing I, as oxytocin receptor antagonists. For example, (2S,4EZ)-1-(tert-butoxycarbonyl)-4-(methoxyimino)-2-pyrrolidinecarboxylic acid and acetamidoxime (preparation of reactants given) in DCM were stirred overnight at room temperature to give the oxadiazole intermediate (60%). N-deprotection using HCl gas, followed by addition of 2'-methyl[1,1'-biphenyl]-4-carboxylic acid and DMAP and separation of the (E)- and (Z)-isomers by column chromatog. afforded (3E,5S)- and (3Z,5S)-II in 34% and 33% yield, resp. The latter displayed binding affinity for the human oxytocin receptor (hOT-R) in vitro with IC₅₀ of 0.009 μM, inhibited oxytocin-induced Ca²⁺ mobilization mediated by hOT-R in vitro with IC₅₀ of 0.004 μM, and reduced oxytocin-induced uterine contractions in non-pregnant female rats by 74.4% ± 4.2% at doses of 30 mg/kg p.o. I are useful in the treatment and/or prevention of disease states mediated by oxytocin, including preterm labor, premature birth, and dysmenorrhea.


IT 84348-37-8P, (2S)-1-(tert-Butoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic acid 364077-84-9P,
 (2R)-1-(tert-Butoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic acid 479079-16-8P, (2S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-N'-hydroxy-4-(methoxyimino)-2-pyrrolidinecarboximidamide 479079-19-1P,
 (2S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-4-(methoxyimino)-2-pyrrolidinecarboxamide 479079-20-4P,
 (2S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-4-(methoxyimino)-2-pyrrolidinecarbonitrile
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of

(biphenylylcarbonyl)(oxadiazolyl)pyrrolidinone
oxime oxytocin receptor antagonists from N-protected
(alkoxyimino)pyrrolidinecarboxylates, carbamidoximes, and
biphenylylcarbonyl chlorides)

RN 84348-37-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) ester,
(2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 364077-84-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) ester,
(2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 479079-16-8 CAPLUS

CN 2-Pyrrolidinecarboximidamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-hydroxy-4-
(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 479079-19-1 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-
(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-20-4 CAPLUS
CN 2-Pyrrolidinecarbonitrile, 1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 479079-40-8P, (3Z,5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime
479079-44-2P 479079-45-3P 479079-78-2P
479079-79-3P, (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[5-((3R)-piperidinyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime
479079-81-7P 479079-87-3P,
(5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[5-(1-piperazinylmethyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-92-0P,
4-[(2S)-2-[5-[(tert-Butoxycarbonyl)amino]methyl]-1,2,4-oxadiazol-3-yl]-4-(methoxyimino)pyrrolidinyl carbonyl]-1,1'-biphenyl 479079-97-5P,
4-[(2S)-2-[5-[(1S)-2-tert-Butoxy-1-[(tert-butoxycarbonyl)amino]ethyl]-1,2,4-oxadiazol-3-yl]-4-(methoxyimino)pyrrolidinyl carbonyl]-1,1'-biphenyl 479080-00-7P, 4-[(2S)-2-[5-[(1S,2R)-2-tert-Butoxy-1-[(tert-butoxycarbonyl)amino]propyl]-1,2,4-oxadiazol-3-yl]-4-(methoxyimino)pyrrolidinyl carbonyl]-1,1'-biphenyl 479080-02-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(oxytocin receptor antagonist; preparation of
(biphenylylcarbonyl)(oxadiazolyl)pyrrolidinone oxime oxytocin receptor
antagonists from N-protected (alkoxyimino)pyrrolidinecarboxylates,
carbamidoximes, and biphenylylcarbonyl chlorides)
RN 479079-40-8 CAPLUS
CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 479079-44-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-45-3 CAPLUS
CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[(3-(4-piperidinyl)-1,2,4-oxadiazol-5-yl)-3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-78-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[3-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester

(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-79-3 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(3R)-3-piperidinyl-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-81-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-87-3 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(1-piperazinylmethyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-92-0 CAPLUS

CN Carbamic acid, [[3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-97-5 CAPLUS


CN Carbamic acid, [(1S)-1-[3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]-2-(1,1-dimethylethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-00-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]-2-(1,1-dimethylethoxy)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 479080-02-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-carboxylic acid,
 3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-
 , ethyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



IT 479079-22-6P, (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479079-23-7P
 , (3E,5S)-1-[(2'-Methyl-[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479079-24-8P,
 (3Z,5S)-1-[(2'-Methyl[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479079-26-0P,
 (5S)-1-[(2'-Chloro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479079-27-1P,
 (5S)-5-(3-Methyl-1,2,4-oxadiazol-5-yl)-1-[(2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)carbonyl]-3-pyrrolidinone O-methyloxime
 479079-28-2P, (3E,5S)-1-[(2'-Fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime
 479079-29-3P, (3Z,5S)-1-[(2'-Fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime
 479079-30-6P, (5S)-1-[(4'-Fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime

479079-31-7P, (5S)-1-[(2'-Chloro-4'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479079-32-8P,
(3Z,5S)-1-[(2'-Chloro-4'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479079-34-0P
, (5S)-1-[(2',4'-Difluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479079-35-1P,
(3Z,5S)-1-[(2',4'-Difluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479079-36-2P,
(3E,5S)-1-[(2',4'-Difluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479079-37-3P,
(5S)-1-[(4'-Fluoro-2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479079-39-5P
, (3E,5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479079-41-9P
479079-42-0P 479079-43-1P,
(5S)-1-[(2'-Chloro-4'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479079-46-4P, (5S)-5-[3-(1-Acetyl-4-piperidinyl)-1,2,4-oxadiazol-5-yl]-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-3-pyrrolidinone O-methyloxime 479079-47-5P, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[3-(1-methyl-4-piperidinyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479079-48-6P, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(phenoxyethyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-49-7P 479079-50-0P,
(5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(methoxymethyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-51-1P,
(5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-(5-phenyl-1,2,4-oxadiazol-3-yl)-3-pyrrolidinone O-methyloxime 479079-52-2P 479079-53-3P
, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-[4-(hydroxymethyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-54-4P
, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(2-hydroxyethyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-55-5P,
(5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-((2S)-2-hydroxy-2-phenylethyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-56-6P, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(2-phenoxyethyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-57-7P, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(2-methoxyethyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-58-8P, (5S)-5-[5-(1-Acetyl-4-piperidinyl)-1,2,4-oxadiazol-3-yl]-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-3-pyrrolidinone O-methyloxime 479079-59-9P, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-60-2P, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(3-thienyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-61-3P, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-3-pyrrolidinone O-methyloxime 479079-62-4P
, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-3-pyrrolidinone O-methyloxime 479079-63-5P,
(5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-(5-methyl-1,2,4-oxadiazol-3-yl)-3-pyrrolidinone O-methyloxime 479079-64-6P 479079-65-7P
479079-66-8P, (5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(1R)-1-(dimethylamino)-2-phenylethyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-67-9P,
(5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-68-0P,
(5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(6-hydroxy-3-pyridinyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-69-1P,
(5S)-1-[(1,1'-Biphenyl)-4-yl)carbonyl]-5-[5-(dimethylamino)methyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-70-4P,

(3Z,5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-71-5P
, (3E,5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-72-6P
479079-73-7P, (5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-74-8P 479079-75-9P,
1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-76-0P,
(5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[5-(1-methyl-4-piperidinyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-77-1P
, (5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[5-vinyl-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-80-6P 479079-82-8P
, (5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[5-((3*S*)-piperidinyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-83-9P
479079-85-1P 479079-86-2P 479079-88-4P,
(5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[5-[(4-methyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-89-5P, (3Z,5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[5-[(4-methyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479079-90-8P,
(5S)-5-[5-[(4-Acetyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-3-yl]-1-[(*(1,1'-biphenyl)-4-yl*)carbonyl]-3-pyrrolidinone O-methyloxime 479079-91-9P, (3Z,5S)-5-[5-[(4-Acetyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-3-yl]-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-3-pyrrolidinone O-methyloxime 479079-93-1P 479079-94-2P
479079-95-3P 479079-96-4P,
4-[(2*S*)-2-[5-[2-[(tert-Butoxycarbonyl)amino]ethyl]-1,2,4-oxadiazol-3-yl]-4-(methoxyimino)pyrrolidinyl]carbonyl]-1,1'-biphenyl 479079-98-6P
, (5S)-5-[5-[(1*S*)-1-Amino-2-tert-butoxyethyl]-1,2,4-oxadiazol-3-yl]-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-3-pyrrolidinone O-methyloxime 479079-99-7P, (5S)-5-[5-[(1*S*)-1-Amino-2-hydroxyethyl]-1,2,4-oxadiazol-3-yl]-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-3-pyrrolidinone O-methyloxime 479080-01-8P,
(5S)-5-[5-[(1*S,2R*)-1-Amino-2-hydroxypropyl]-1,2,4-oxadiazol-3-yl]-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-3-pyrrolidinone O-methyloxime 479080-03-0P 479080-04-1P,
(5S)-5-[3-Benzyl-1,2,4-oxadiazol-5-yl]-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-3-pyrrolidinone O-methyloxime 479080-05-2P,
(5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[3-[(2-furylmethyl)sulfanyl]methyl]-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-06-3P,
(5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[3-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-08-5P, (5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[3-[(2-pyridinylsulfanyl)methyl]-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-10-9P,
(5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-11-0P,
(5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[3-[(2-thienylsulfanyl)methyl]-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-13-2P
, (5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[3-[2-(3,5-dimethyl-1*H*-pyrazol-1-yl)ethyl]-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-14-3P, (5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[3-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-15-4P,
(5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[3-(5-methyl-3-isoxazolyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-16-5P,
(5S)-1-[(*(1,1'-Biphenyl)-4-yl*)carbonyl]-5-[3-(2-thienylmethyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-17-6P,

(5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479080-18-7P,
 (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[3-[(2-furylmethyl)sulfonyl]methyl]-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-19-8P,
 (5S)-5-[3-(Aminomethyl)-1,2,4-oxadiazol-5-yl]-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-3-pyrrolidinone O-methyloxime 479080-21-2P,
 (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[3-[hydroxy(phenyl)methyl]-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-22-3P,
 (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[3-(1-hydroxypropyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-24-5P,
 (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[3-(hydroxymethyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-25-6P,
 (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[3-((1S,2R)-2-hydroxycyclohexyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-27-8P
 , (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[3-(3-piperidinyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-29-0P,
 (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[3-(2-piperidinyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-31-4P,
 (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-3-pyrrolidinone O-methyloxime 479080-33-6P
 479080-35-8P, (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-(1,3,4-oxadiazol-2-yl)-3-pyrrolidinone O-methyloxime 479080-37-0P,
 (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-(1,2,4-oxadiazol-3-yl)-3-pyrrolidinone O-methyloxime 479080-38-1P,
 (5S)-1-[(2'-Methyl[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinone O-methyloxime 479080-39-2P,
 (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime 479080-41-6P,
 (5S)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]-3-pyrrolidinone O-methyloxime 479080-42-7P,
 (3Z)-1-[(1,1'-Biphenyl)-4-yl]carbonyl]-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone O-methyloxime

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(oxytocin receptor antagonist; preparation of (biphenylcarbonyl)(oxadiazolyl)pyrrolidinone oxime oxytocin receptor antagonists from N-protected (alkoxyimino)pyrrolidinecarboxylates, carbamidoximes, and biphenylcarbonyl chlorides)

RN 479079-22-6 CAPLUS

CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-23-7 CAPLUS

CN 3-Pyrrolidinone, 1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (3E,5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 479079-24-8 CAPLUS

CN 3-Pyrrolidinone, 1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 479079-26-0 CAPLUS

CN 3-Pyrrolidinone, 1-[(2'-chloro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-27-1 CAPLUS

CN 3-Pyrrolidinone, 5-(3-methyl-1,2,4-oxadiazol-5-yl)-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl-, 3-(O-methyloxime), (5S)-(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-28-2 CAPLUS

CN 3-Pyrrolidinone, 1-[2'-(fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (3E,5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 479079-29-3 CAPLUS

CN 3-Pyrrolidinone, 1-[(2'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 479079-30-6 CAPLUS

CN 3-Pyrrolidinone, 1-[(4'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-31-7 CAPLUS

CN 3-Pyrrolidinone, 1-[(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-32-8 CAPLUS

CN 3-Pyrrolidinone, 1-[(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 479079-34-0 CAPLUS

CN 3-Pyrrolidinone, 1-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 479079-35-1 CAPLUS


CN 3-Pyrrolidinone, 1-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 479079-36-2 CAPLUS
CN 3-Pyrrolidinone, 1-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (3E,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 479079-37-3 CAPLUS
CN 3-Pyrrolidinone, 1-[(4'-fluoro-2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-39-5 CAPLUS

CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (3E,5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 479079-41-9 CAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-, 2-[5-[(2S)-1-[(1,1'-biphenyl)-4-ylcarbonyl]-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-3-yl]ethyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 479079-42-0 CAPLUS


CN Glycine, 2-[5-[(2S)-1-[(1,1'-biphenyl)-4-ylcarbonyl]-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-3-yl]ethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-43-1 CAPLUS
CN 3-Pyrrolidinone, 1-[(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-46-4 CAPLUS
CN 3-Pyrrolidinone, 5-[3-(1-acetyl-4-piperidinyl)-1,2,4-oxadiazol-5-yl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-47-5 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-(1-methyl-4-

piperidinyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-48-6 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(phenoxy methyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-49-7 CAPLUS

CN Formamide, N-[(3-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-50-0 CAPLUS

CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[5-(methoxymethyl)-

1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-51-1 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-(5-phenyl-1,2,4-oxadiazol-3-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-52-2 CAPLUS

CN Acetamide, N-[3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-53-3 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-[4-(hydroxymethyl)phenyl]-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)-

(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-54-4 CAPLUS

CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[5-(2-hydroxyethyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-55-5 CAPLUS

CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[5-((2S)-2-hydroxy-2-phenylethyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-56-6 CAPLUS

CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[5-(2-phenoxyethyl)-

1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-57-7 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(2-methoxyethyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-58-8 CAPLUS

CN 3-Pyrrolidinone, 5-[5-(1-acetyl-4-piperidinyl)-1,2,4-oxadiazol-3-yl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 479079-59-9 CAPLUS


CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-60-2 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(3-thienyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-61-3 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-62-4 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-63-5 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-(5-methyl-1,2,4-oxadiazol-3-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-64-6 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(hydroxyphenylmethyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-65-7 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(1-hydroxy-2-phenylethyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-66-8 CAPLUS
CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[5-[(1R)-1-(dimethylamino)-2-phenylethyl]-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-67-9 CAPLUS
CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[5-[(3-pyridinyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-68-0 CAPLUS
CN 2(1H)-Pyridinone, 5-[3-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-69-1 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-
[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)-
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-70-4 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-
[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime),
(3Z,5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 479079-71-5 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-

[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime),
(3E,5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 479079-72-6 CAPLUS

CN 2,6-Piperazinedione, 4-[[3-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-73-7 CAPLUS


CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-74-8 CAPLUS
CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]- γ -[(1,1-dimethylethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-75-9 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime) (CA INDEX NAME)



RN 479079-76-0 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(1-methyl-4-piperidinyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-77-1 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-(5-ethenyl-1,2,4-oxadiazol-3-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-80-6 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-[(3R)-1-methyl-3-piperidinyl]-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-82-8 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(3S)-3-piperidinyl-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-83-9 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-[(3S)-1-methyl-3-piperidinyl]-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479079-85-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 479079-86-2 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-88-4 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-[(4-methyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5*S*) - (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-89-5 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-[(4-methyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (3*Z*,5*S*) - (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 479079-90-8 CAPLUS
CN 3-Pyrrolidinone, 5-[5-[(4-acetyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-3-yl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-, 3-(O-methyloxime), (5*S*) - (CA INDEX NAME)

NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-91-9 CAPLUS

CN 3-Pyrrolidinone, 5-[5-[(4-acetyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-3-yl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 479079-93-1 CAPLUS

CN 1-Piperidinepropanamide, N-[(3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-94-2 CAPLUS

CN Propanamide, N-[3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]methyl]-3-(dimethylamino)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-95-3 CAPLUS

CN Acetamide, N-[3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]methyl]-2-(dimethylamino)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479079-96-4 CAPLUS


CN Carbamic acid, [2-[3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-98-6 CAPLUS
CN 3-Pyrrolidinone, 5-[5-[(1S)-1-amino-2-(1,1-dimethylethoxy)ethyl]-1,2,4-oxadiazol-3-yl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479079-99-7 CAPLUS
CN 3-Pyrrolidinone, 5-[5-[(1S)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-3-yl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 479080-01-8 CAPLUS
CN 3-Pyrrolidinone, 5-[5-[(1S,2R)-1-amino-2-hydroxypropyl]-1,2,4-oxadiazol-3-yl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-03-0 CAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479080-04-1 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-(phenylmethyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479080-05-2 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-[(2-furanyl methyl)thio]methyl]-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479080-06-3 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479080-08-5 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-[((2-pyridinylthio)methyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479080-10-9 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479080-11-0 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-[(2-thienylthio)methyl]-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479080-13-2 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-[(2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 479080-14-3 CAPLUS


CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-15-4 CAPLUS
CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[3-(5-methyl-3-isoxazolyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-16-5 CAPLUS
CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-[3-(2-thienylmethyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-17-6 CAPLUS
CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-18-7 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-[(2-furanyl methyl)sulfonyl]methyl]-1,2,4-oxadiazol-5-yl-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-19-8 CAPLUS
CN 3-Pyrrolidinone, 5-[3-(aminomethyl)-1,2,4-oxadiazol-5-yl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-21-2 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-(hydroxyphenylmethyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-22-3 CAPLUS
CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-[3-(1-hydroxypropyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-24-5 CAPLUS
CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-[3-(hydroxymethyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-25-6 CAPLUS
CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-[3-[(1S,2R)-2-hydroxycyclohexyl]-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-27-8 CAPLUS
CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-[3-(3-piperidinyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 479080-29-0 CAPLUS
CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-[3-(2-piperidinyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 479080-31-4 CAPLUS
CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-(4,5-dihydro-5-thioxo-1,3,4-oxadiazol-2-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 479080-33-6 CAPLUS
CN 1,3,4-Oxadiazol-2(3H)-one, 5-[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 479080-35-8 CAPLUS
CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-(1,3,4-oxadiazol-2-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 479080-37-0 CAPLUS
CN 3-Pyrrolidinone, 1-((1,1'-biphenyl)-4-ylcarbonyl)-5-(1,2,4-oxadiazol-3-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479080-38-1 CAPLUS

CN 3-Pyrrolidinone, 1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 479080-39-2 CAPLUS

CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 479080-41-6 CAPLUS


CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 479080-42-7 CAPLUS
CN 3-Pyrrolidinone, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-, 3-(O-methyloxime), (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




IT 13726-69-7, (2S,4R)-1-(tert-Butoxycarbonyl)-4-hydroxy-2-pyrrolidinecarboxylic acid 147266-92-0,
(2R,4S)-1-(tert-Butoxycarbonyl)-4-hydroxy-2-pyrrolidinecarboxylic acid 479079-84-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (biphenylcarbonyl)(oxadiazolyl)pyrrolidinone oxime oxytocin receptor antagonists from N-protected (alkoxyimino)pyrrolidinecarboxylates, carbamidoximes, and biphenylcarbonyl chlorides)

RN 13726-69-7 CAPLUS


CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 147266-92-0 CAPLUS
CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) ester,
(2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 479079-84-0 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[5-(3-piperidinyl)-
1,2,4-oxadiazol-3-yl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:736228 CAPLUS Full-text
DN 137:247923
TI Preparation of pyrrolidine ester derivatives with oxytocin modulating
activity
IN Schwarz, Matthias; Quattropani, Anna; Scheer, Alexander; Dorbais, Jerome;
Pomel, Vincent
PA Applied Research Systems Ars Holding N.V., Neth. Antilles
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074741	A1	20020926	WO 2002-EP3005	20020319
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2440002 A1 20020926 CA 2002-2440002 20020319
 AU 2002256685 A1 20021003 AU 2002-256685 20020319
 AU 2002256685 B2 20080124
 EP 1390347 A1 20040225 EP 2002-726184 20020319
 EP 1390347 B1 20080507
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004525132 T 20040819 JP 2002-573750 20020319
 EP 1829861 A2 20070905 EP 2007-12082 20020319
 EP 1829861 A3 20090121
 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
 NL, PT, SE, TR, AL, LT, LV, MK, RO, SI
 AT 394371 T 20080515 AT 2002-726184 20020319
 ES 2303854 T3 20080901 ES 2002-726184 20020319
 US 20040147511 A1 20040729 US 2004-471290 20040223
 US 7189754 B2 20070313
 US 20070129381 A1 20070607 US 2007-620359 20070105
 PRAI EP 2001-106888 A 20010320
 EP 2002-726184 A3 20020319
 WO 2002-EP3005 W 20020319
 US 2004-471290 A3 20040223
 OS MARPAT 137:247923
 GI



AB Pyrrolidine esters I [X = CR₆R₇, NOR₆, NNR₆R₇, where R₆, R₇ = H, alkyl, (thio)alkoxy, halo, cyano, (hetero)cycloalkyl, aryl, etc. or NR₆R₇ = heterocyclyl; R = alkyl, alkenyl, alkynyl, (hetero)cyclyl, (hetero)aryl, etc.; R₁ = alkyl, (hetero)aryl, cycloalkyl, acyl, etc.; R₂-R₅ = H, halo, alkyl], including isomers, enantiomers, diastereomers and racemate forms and pharmaceutically-acceptable salts, were prepared for use in pharmaceutical compns. for the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters I to antagonize the oxytocin receptor. Thus, Me (2S,4E/4Z)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxylate, prepared via coupling of Me (2S,4EZ)-4-(methoxyimino)-2-pyrrolidinecarboxylate with 2'-methyl(1,1'-biphenyl)-4-carboxylic acid, showed IC₅₀ = 0.036 and 0.012 μM (4E/4Z isomers resp.) for binding of the human oxytocin receptor.


IT 461418-00-8P 461418-01-9P 461418-05-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrrolidine ester derivs. with oxytocin modulating activity)

RN 461418-00-8 CAPLUS

CN L-Proline, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 461418-01-9 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 461418-05-3 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



IT 461418-02-0P 461418-03-1P 461418-04-2P
461418-09-7P 461418-11-1P 461418-18-8P
461418-24-6P 461418-38-2P 461418-41-7P
461418-44-0P 461418-48-4P 461418-50-8P
461418-51-9P 461418-52-0P 461418-53-1P
461418-54-2P 461418-55-3P 461418-56-4P
461418-57-5P 461418-58-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrrolidine ester derivs. with oxytocin modulating activity)

RN 461418-02-0 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, methyl ester, (4E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 461418-03-1 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, methyl ester, (4Z)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 461418-04-2 CAPLUS

CN L-Proline, 1-[(2'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 461418-09-7 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 2-methylpropyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 461418-11-1 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, cyclopentyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 461418-18-8 CAPLUS

CN L-Proline, 1-[4'-fluoro[1,1'-biphenyl]-4-yl]carbonyl]-4-(methoxyimino)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 461418-24-6 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[4-(5-pyrimidinyl)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 461418-38-2 CAPLUS

CN L-Proline, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, ethyl ester

(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 461418-41-7 CAPLUS

CN L-Proline, 1-[(2'-chloro[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 461418-44-0 CAPLUS


CN L-Proline, 1-[(2'-cyano[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 461418-48-4 CAPLUS
CN L-Proline, 4-(methoxyimino)-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 461418-50-8 CAPLUS
CN L-Proline, 1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 461418-51-9 CAPLUS
CN L-Proline, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 461418-52-0 CAPLUS

CN L-Proline, 1-[2',3-dimethyl[1,1'-biphenyl]-4-yl]carbonyl]-4-(methoxyimino)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 461418-53-1 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[3-methyl[1,1'-biphenyl]-4-yl]carbonyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 461418-54-2 CAPLUS


CN L-Proline, 1-[3',4'-dichloro[1,1'-biphenyl]-4-yl]carbonyl]-4-(methoxyimino)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 461418-55-3 CAPLUS
CN L-Proline, 4-(methoxyimino)-1-[4-(2-pyridinyl)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 461418-56-4 CAPLUS
CN L-Proline, 4-(methoxyimino)-1-[4-(3-methyl-2-pyridinyl)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 461418-57-5 CAPLUS
CN L-Proline, 1-[(2'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, methyl ester, (4Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 461418-58-6 CAPLUS
CN L-Proline, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 1-methylpropyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 13726-69-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolidine ester derivs. with oxytocin modulating activity)
RN 13726-69-7 CAPLUS
CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 84348-37-8P 102195-80-2P 364077-84-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrolidine ester derivs. with oxytocin modulating activity)
 RN 84348-37-8 CAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) ester,
 (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 102195-80-2 CAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 364077-84-9 CAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) ester,
 (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2001:747746 CAPLUS Full-text
 DN 135:303763
 TI Preparation of pyrrolidines as inhibitors of Bax function.
 IN Halazy, Serge; Schwarz, Matthias; Quattropani, Anna; Thomas, Russel;
 Baxter, Anthony; Bombrun, Agnes
 PA Applied Research Systems Ars Holding N.V., Neth. Antilles
 SO PCT Int. Appl., 221 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001074769	A1	20011011	WO 2001-EP3170	20010320
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2401137	A1	20011011	CA 2001-2401137	20010320
	EP 1268418	A1	20030102	EP 2001-925491	20010320
	EP 1268418	B1	20060614		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003529584	T	20031007	JP 2001-572464	20010320
	AT 329899	T	20060715	AT 2001-925491	20010320
	AU 2001252222	B2	20061102	AU 2001-252222	20010320
	ES 2262640	T3	20061201	ES 2001-925491	20010320
	US 20030171309	A1	20030911	US 2003-240000	20030428
	US 7018988	B2	20060328		
PRAI	EP 2000-106033	A	20000327		
	WO 2001-EP3170	W	20010320		
OS	MARPAT	135:303763			
GI					




AB Title compds. [I; X = O, S, CR6R7, NOR6, NR6R7; A = CO, CO₂, C(:NH), CONH, CSNH, SO₂, SO₂NH, CH₂; B = CONR8R9, specified bicyclic heterocyclyl; R1 = (substituted) alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, acyl, etc.; R2-R5 = H, halo, alkyl, alkoxy; R6, R7 = H, (substituted) alkyl, alkenyl, alkynyl, alkoxy, halo, cyano, NO₂, acyl, etc.; R8, R9 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; R6R7N, R8R9N = 3-8 membered (substituted) (fused) heterocyclyl], were prepared Thus, (2S,4EZ)-2-[(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]-4-(methoxyimino)-N-pentyl-1-pyrrolidinecarboxamide [general preparation from (2S,4EZ)-1-(tert-butoxycarbonyl)-4-(methoxyimino)-2-pyrrolidinecarboxylic acid, 1-isocyanatopentane, and 1-(1,3-benzodioxol-5-ylmethyl)piperazine given] at 10 μM gave 59% inhibition of cytochrome C release triggered by Bid-induced Bax activation.

IT 365546-35-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrrolidines as inhibitors of Bax function)

RN 365546-35-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



IT 364071-15-8P 364071-16-9P 364071-17-0P
 364071-19-2P 364071-31-8P 364071-33-0P
 364071-35-2P 364071-37-4P 364071-39-6P
 364071-41-0P 364071-43-2P 364071-45-4P
 364071-47-6P 364071-49-8P 364071-51-2P
 364071-53-4P 364071-55-6P 364071-57-8P
 364071-71-6P 364071-73-8P 364071-79-4P
 364071-81-8P 364071-83-0P 364071-91-0P
 364071-97-6P 364072-01-5P 364072-03-7P
 364072-05-9P 364072-11-7P 364072-17-3P
 364072-33-3P 364072-37-7P 364072-53-7P

364072-54-8P 364072-61-7P 364072-63-9P
364072-67-3P 364072-71-9P 364072-73-1P
364072-87-7P 364072-90-2P 364073-25-6P
364073-28-9P 364073-30-3P 364073-46-1P
364073-58-5P 364073-63-2P 364073-70-1P
364073-73-4P 364073-79-0P 364074-08-8P
364074-15-7P 364074-16-8P 364074-19-1P
364074-20-4P 364074-22-6P 364074-23-7P
364074-28-2P 364074-29-3P 364074-34-0P
364074-35-1P 364074-41-9P 364074-43-1P
364074-45-3P 364074-55-5P 364074-83-9P
364074-89-5P 364074-94-2P 364074-98-6P
364075-03-6P 364075-04-7P 364075-13-8P
364075-17-2P 364075-21-8P 364075-27-4P
364075-30-9P 364075-43-4P 364075-45-6P
364075-51-4P 364075-55-8P 364075-59-2P
364075-86-5P 364075-96-7P 364076-10-8P
364076-14-2P 364076-16-4P 364076-18-6P
364076-20-0P 364076-22-2P 364076-25-5P
364076-27-7P 364076-28-8P 364076-30-2P
364076-31-3P 364076-32-4P 364076-33-5P
364076-35-7P 364076-37-9P 364076-38-0P
364076-40-4P 364076-41-5P 364076-42-6P
364076-43-7P 364076-44-8P 364076-46-0P
364076-47-1P 364076-49-3P 364076-52-8P
364076-53-9P 364076-54-0P 364076-55-1P
364076-57-3P 364076-58-4P 364076-59-5P
364076-61-9P 364076-62-0P 364076-63-1P
364076-64-2P 364076-66-4P 364076-68-6P
364076-69-7P 364076-70-0P 364076-72-2P
364076-74-4P 364076-75-5P 364076-76-6P
364076-77-7P 364076-78-8P 364076-80-2P
364076-81-3P 364076-82-4P 364076-89-1P
364076-92-6P 364076-94-8P 364076-99-3P
364077-00-9P 364077-01-0P 364077-02-1P
364077-03-2P 364077-04-3P 364077-05-4P
364077-06-5P 364077-07-6P 364077-08-7P
364077-09-8P 364077-10-1P 364077-11-2P
364077-12-3P 364077-13-4P 364077-14-5P
364077-15-6P 364077-16-7P 364077-17-8P
364077-18-9P 364077-19-0P 364077-20-3P
364077-21-4P 364077-22-5P 364077-23-6P
364077-24-7P 364077-25-8P 364077-26-9P
364077-27-0P 364077-28-1P 364077-29-2P
364077-30-5P 364077-31-6P 364077-32-7P
364077-33-8P 364077-34-9P 364077-35-0P
364077-36-1P 364077-37-2P 364077-38-3P
364077-39-4P 364077-40-7P 364077-41-8P
364077-42-9P 364077-43-0P 364077-44-1P
364077-45-2P 364077-46-3P 364077-47-4P
364077-48-5P 364077-49-6P 364077-50-9P
364077-51-0P 364077-52-1P 364077-53-2P
364077-54-3P 364077-55-4P 364077-56-5P
364077-57-6P 364077-58-7P 364077-59-8P
364077-60-1P 364077-61-2P 364077-62-3P
364077-63-4P 364077-64-5P 364077-65-6P
364077-66-7P 364077-67-8P 364077-68-9P
364077-69-0P 364077-70-3P 364077-71-4P
364077-72-5P 364077-73-6P 364077-74-7P
364077-75-8P 364077-76-9P 364077-77-0P

364077-78-1P 364077-79-2P 364077-80-5P
364077-81-6P 364077-82-7P 364077-83-8P
365456-63-9P 365456-67-3P 365456-73-1P
365456-76-4P 365531-76-6P 365531-99-3P
365546-36-7P 365546-37-8P 365546-38-9P
365546-41-4P 365546-42-5P 365546-46-9P
365546-47-0P 365546-48-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidines as inhibitors of Bax function)

RN 364071-15-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-methoxyethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-16-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S,4E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 364071-17-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S,4Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 364071-19-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[2-(diethylamino)ethyl]-4-[(4-methoxyphenyl)methoxy]imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-31-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-4-(methoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S,4E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 364071-33-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-4-(methoxyimino)-1-

[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S, 4Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 364071-35-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-benzoyl-N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-37-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxyethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364071-39-6 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S,4E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 364071-41-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S,4Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 364071-43-2 CAPLUS
CN 3-Pyrrolidinone, 5-(1H-benzimidazol-2-yl)-1-((1,1'-biphenyl)-4-ylcarbonyl)-3-(O-methyloxime), (3E,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 364071-45-4 CAPLUS
CN 3-Pyrrolidinone, 5-(1H-benzimidazol-2-yl)-1-((1,1'-biphenyl)-4-ylcarbonyl)-3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 364071-47-6 CAPLUS
CN 3-Pyrrolidinone, 5-(1H-benzimidazol-2-yl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364071-49-8 CAPLUS
CN 3-Pyrrolidinone, 5-(1-methyl-1H-benzimidazol-2-yl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364071-51-2 CAPLUS

CN 3-Pyrrolidinone, 5-(7-hydroxy-1H-benzimidazol-2-yl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-53-4 CAPLUS

CN 3-Pyrrolidinone, 5-(1,4-dihydro-2-quinazolinyl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-55-6 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-(1-methyl-1H-benzimidazol-2-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-57-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(hydroxyimino)-N-(2-hydroxy-2-phenylethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-71-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-4-[(2-propen-1-yloxy)imino]-N-[2-(1H-pyrrol-1-yl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-73-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[3,4-dichlorophenyl]methoxy]imino]-N-(2-furanylmethyl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-79-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-N-(2-furanyl methyl)-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-81-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-(diethylamino)ethyl]-1-(4-phenoxybenzoyl)-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-83-0 CAPLUS

CN Benzonitrile, 4-[(2S)-2-[(4-(3,4-dichlorophenyl)-1-piperazinyl]carbonyl]-4-[(phenylmethoxy)imino]-1-pyrrolidinyl]carbonyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-91-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-(diethylamino)ethyl]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-97-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-N-(9-ethyl-9H-carbazol-3-yl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-01-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[(1,1-dimethylethoxy)imino]-N-(2-methoxyethyl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-03-7 CAPLUS

CN 3-Pyrrolidinone, 5-[(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)carbonyl]-1-benzoyl-, 3-[O-[(3,4-dichlorophenyl)methyl]oxime], (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-05-9 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[[(2S)-4-(ethoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-2-pyrrolidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364072-11-7 CAPLUS


CN 3-Pyrrolidinone, 5-[(4-(3,4-dichlorophenyl)-1-piperazinyl)carbonyl]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, 3-[O-(phenylmethyl)oxime], (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364072-17-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(4,6-dimethoxy-2-pyrimidinyl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364072-33-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1-(4-cyanobenzoyl)-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364072-37-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-[(3,4-dichlorophenyl)methoxy]imino]-N-[2-(1H-pyrrol-1-yl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-53-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-2,1,3-benzothiadiazol-4-yl-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-54-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-N-6-quinolinyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-61-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-N-2-propen-1-yl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364072-63-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-N-(2-thienylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364072-67-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-furanyl methyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364072-71-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-furanyl methyl)-4-(methoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-73-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-N-methyl-N-(phenylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-87-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-(diethylamino)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-90-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(3,4-dimethoxyphenyl)methyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364073-25-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-[(3,4-dichlorophenyl)methoxy]imino-N-[2-(diethylamino)ethyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364073-28-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364073-30-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-N-(phenylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364073-46-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-benzoyl-4-[(3,4-dichlorophenyl)methoxy]imino-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364073-58-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-4-[(3,4-dichlorophenyl)methoxy]imino-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364073-63-2 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364073-70-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-benzoyl-N-[2-(diethylamino)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364073-73-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-2,1,3-benzothiadiazol-4-yl-1-(4-cyanobenzoyl)-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364073-79-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-N-[2-(diethylamino)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364074-08-8 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-benzoyl-N-(2-furanyl methyl)-4-[(4-methoxyphenyl)methoxy]imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364074-15-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-[(1,1-dimethylethoxy)imino]-1-[(2-ethoxy-1-naphthalenyl)carbonyl]-N-(9-ethyl-9H-carbazol-3-yl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364074-16-8 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-benzoyl-N-[2-(diethylamino)ethyl]-4-(ethoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-19-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-4-[(3,4-dichlorophenyl)methoxy]imino]-N-(1-naphthalenylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-20-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-2,1,3-benzothiadiazol-4-yl-1-benzoyl-4-[(4-methoxyphenyl)methoxy]imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-22-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(ethoxyimino)-N-(9-ethyl-9H-carbazol-3-yl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-23-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-benzoyl-4-(ethoxyimino)-N-(9-ethyl-9H-carbazol-3-yl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-28-2 CAPLUS

CN 3-Pyrrolidinone, 1-benzoyl-5-[(4-(3,4-dichlorophenyl)-1-piperazinyl]carbonyl]-, 3-(O-ethyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-29-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-34-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-35-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[(4-methoxyphenyl)methoxy]imino]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-41-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-1-(4-phenoxybenzoyl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-43-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-45-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(ethoxyimino)-N-(9-ethyl-9H-carbazol-3-yl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-55-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(phenylmethoxy)imino]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-83-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(ethoxyimino)-N-(9-ethyl-9H-carbazol-3-yl)-1-(4-phenoxybenzoyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-89-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(3,4-dimethoxyphenyl)methyl]-4-[(1,1-dimethylethoxy)imino]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-94-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(4,6-dimethoxy-2-pyrimidinyl)-4-(ethoxyimino)-1-(4-phenoxybenzoyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-98-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-(9-ethyl-9H-carbazol-3-yl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-03-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-04-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(4-methoxyphenyl)methoxy]imino]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-13-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-4-(methoxyimino)-1-(4-phenoxybenzoyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-17-2 CAPLUS

CN 3-Pyrrolidinone, 5-[{4-[1,3-benzodioxol-5-ylmethyl]-1-piperazinyl}carbonyl]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, 3-[O-(1,1-dimethylethyl)oxime], (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-21-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-benzoyl-4-[(2-propen-1-yloxy)imino]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-27-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2-ethoxy-1-naphthalenyl)carbonyl]-N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-30-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-43-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-cyclopropyl-4-[(1,1-dimethylethoxy)imino]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-45-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[(4-methoxyphenyl)methoxy]imino]-1-(4-phenoxybenzoyl)-N-[4-(1H-pyrrol-1-yl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-51-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(3,4-dimethoxyphenyl)methyl]-4-(ethoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-55-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-59-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-N-(2-methoxyethyl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-86-5 CAPLUS

CN 3-Pyrrolidinone, 1-benzoyl-5-(4-morpholinylcarbonyl)-, 3-[O-[(3,4-dichlorophenyl)methyl]oxime], (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-96-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[[(3,4-dichlorophenyl)methoxy]imino]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-10-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(2-propen-1-yloxy)imino]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-14-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-16-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-3-ylcarbonyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-18-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-benzoylbenzoyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-20-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-(3-phenoxybenzoyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-22-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-(2-phenoxybenzoyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-25-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-27-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxyethyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-28-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxyethyl)-4-(methoxyimino)-N-methyl-1-

[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-30-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-(trans-4-hydroxycyclohexyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-31-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(1R,2R)-2-(hydroxymethyl)cyclohexyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364076-32-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxy-3-phenoxypropyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364076-33-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-3-phenoxypropyl)-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364076-35-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-37-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(1-hydroxycyclohexyl)methyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-38-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1-hydroxycyclohexyl)methyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-40-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-41-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-42-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-43-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(2-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-44-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-(2,3-dihydroxypropyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-46-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-47-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-49-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-(2-hydroxypropyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-52-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[2-hydroxy-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-53-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-54-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-55-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-1-[4-(2-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364076-57-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[3-[4-(acetylamino)phenoxy]-2-hydroxypropyl]-1-[(1,1'-biphenyl)-4-ylcarbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-58-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-(acetamino)phenoxy]-2-hydroxypropyl]-4-(methoxyimino)-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-59-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-(acetamino)phenoxy]-2-hydroxypropyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-61-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-62-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364076-63-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-64-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(2-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-66-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(3-hydroxypropyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-68-6 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[(4-hydroxy-4-phenyl-1-piperidinyl)carbonyl]-, 3-(O-methylloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-69-7 CAPLUS

CN 3-Pyrrolidinone, 5-[(4-hydroxy-4-phenyl-1-piperidinyl)carbonyl]-1-[4-(4-pyridinyl)benzoyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-70-0 CAPLUS

CN 3-Pyrrolidinone, 5-[(4-hydroxy-4-phenyl-1-piperidinyl)carbonyl]-1-[4-(3-pyridinyl)benzoyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-72-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(1S,2S)-2-hydroxycyclohexyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-74-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxyethyl)-4-(methoxyimino)-N-(phenylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-75-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxyethyl)-4-(methoxyimino)-N-(phenylmethyl)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-76-6 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[(3-hydroxy-1-piperidinyl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-77-7 CAPLUS

CN 3-Pyrrolidinone, 5-[(3-hydroxy-1-piperidinyl)carbonyl]-1-[4-(4-pyridinyl)benzoyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-78-8 CAPLUS

CN 3-Pyrrolidinone, 5-[(3-hydroxy-1-piperidinyl)carbonyl]-1-[4-(3-pyridinyl)benzoyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-80-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([(1,1'-biphenyl)-4-ylcarbonyl]-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364076-81-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-4-(methoxyimino)-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA
INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364076-82-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-89-1 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[(4-hydroxy-1-piperidinyl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-92-6 CAPLUS

CN β-Alaninamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-94-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(4-hydroxybutyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-99-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-00-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(1R,2S)-2-(hydroxymethyl)cyclohexyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-01-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-02-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1S,2R,3S,4R)-3-(aminocarbonyl)bicyclo[2.2.1]hept-5-en-2-yl]-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-03-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1S,2S,3R,4R)-3-(aminocarbonyl)bicyclo[2.2.1]hept-5-en-2-yl]-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364077-04-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-05-4 CAPLUS
CN Propanoic acid, 3-[[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]carbonyl]amino]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-06-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R,2S)-2-(aminocarbonyl)cyclohexyl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-07-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxy-1-methylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-08-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-09-8 CAPLUS

CN Butanoic acid, 4-[[[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364077-10-1 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-11-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(2-naphthalenyl)ethyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-12-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-1-methylethyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-13-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-14-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-15-6 CAPLUS

CN 3-Pyrrolidinone, 5-[(4-hydroxy-1-piperidinyl)carbonyl]-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-16-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1S,2S,3R,4R)-3-(aminocarbonyl)bicyclo[2.2.1]hept-5-en-2-yl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-17-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-18-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxypropyl)-4-(methoxyimino)-1-[(2'-

methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-19-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2,3-dihydroxypropyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-20-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-(3-hydroxypropyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-21-4 CAPLUS
CN Glycinamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-L-prolyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-22-5 CAPLUS
CN Glycinamide, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-
L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-23-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-hydroxy-2-
(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-24-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(1S,2R,3S,4R)-3-(hydroxymethyl)bicyclo[2.2.1]hept-2-yl]-4-(methoxyimino)-(2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-25-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1R,2S,3R,4S)-3-(hydroxymethyl)bicyclo[2.2.1]hept-2-yl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-(2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364077-26-9 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-(trans-4-hydroxycyclohexyl)-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-(2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-27-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R,2R)-2-(hydroxymethyl)cyclohexyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-28-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-3-phenoxypropyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-29-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-30-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-31-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)ethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-32-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)ethyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-33-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-34-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-35-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-36-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2'-cyano[1,1'-biphenyl]-4-yl)carbonyl]-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-37-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3',4'-dichloro[1,1'-biphenyl]-4-yl)carbonyl]-
N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-38-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-39-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-40-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-41-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2'-cyano[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-42-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(3',4'-dichloro[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-43-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-44-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-45-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(3',4'-dichloro[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-46-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-47-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX
NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-48-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-(methoxyimino)-, (2S)- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-49-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-(methoxyimino)-, (2S)- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-50-9 CAPLUS

CN Glycinamide, 1-[2',6'-dimethyl[1,1'-biphenyl]-4-yl]carbonyl]-4-(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-51-0 CAPLUS

CN Glycinamide, 1-[2',3'-dimethyl[1,1'-biphenyl]-4-yl]carbonyl]-4-(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-52-1 CAPLUS

CN β-Alaninamide, 1-[2',6'-dimethyl[1,1'-biphenyl]-4-yl]carbonyl]-4-

(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-53-2 CAPLUS

CN β -Alaninamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-54-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-55-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-56-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2'-cyano[1,1'-biphenyl]-4-yl)carbonyl]-N-[(1R,2R)-2-(hydroxymethyl)cyclohexyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-57-6 CAPLUS
CN 3-Pyrrolidinone, 5-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-58-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-59-8 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-60-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-61-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-62-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-

N-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-63-4 CAPLUS

CN Phenylalanine, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-64-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1R,2S)-2-(aminocarbonyl)cyclohexyl]-1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-65-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1R,2S)-2-(aminocarbonyl)cyclohexyl]-1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-66-7 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[[(2S)-2-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-4-(methoxyimino)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-67-8 CAPLUS

CN 3-Pyrrolidinone, 1-[{(3',4'-dichloro[1,1'-biphenyl]-4-yl)carbonyl}-5-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-68-9 CAPLUS

CN 3-Pyrrolidinone, 1-[{(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl}-5-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-69-0 CAPLUS

CN 3-Pyrrolidinone, 1-[{(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl}-5-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-70-3 CAPLUS

CN 3-Pyrrolidinone, 1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-5-[(4-[4-(trifluoromethyl)phenyl]-1-piperazinyl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-71-4 CAPLUS

CN 3-Pyrrolidinone, 1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-5-[(4-[3-(trifluoromethyl)phenyl]-1-piperazinyl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-72-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-73-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-N-methyl-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-74-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-N,N-dimethyl-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-75-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(3R)-3-hydroxy-3-phenylpropyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-76-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(3S)-3-hydroxy-3-phenylpropyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-77-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(3R)-3-hydroxy-3-phenylpropyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-78-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(3S)-3-hydroxy-3-phenylpropyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-79-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-80-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2'-chloro[1,1'-biphenyl]-4-yl)carbonyl]-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-81-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxyphenyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-82-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-(hydroxymethyl)phenyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-83-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-N-(2-phenylethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 365456-63-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-N-[2-(phenylamino)ethyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 365456-67-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-N-[2-(phenylamino)ethyl]-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 365456-73-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-N-[2-(phenylamino)ethyl]-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365456-76-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-N-[2-(phenylamino)ethyl]-1-[4-(2-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 365531-76-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S,4Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 365531-99-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S,4E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 365546-36-7 CAPLUS

CN 3-Pyrrolidinone, 5-(1H-benzimidazol-2-yl)-1-[(1,1'-biphenyl)-4-ylcarbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 365546-37-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-hydroxy-1-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.




RN 365546-38-9 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[2-(diethylamino)ethyl]-4-[(4-methoxyphenyl)methoxy]imino-, (2S)- (CA INDEX NAME)

PAGE 1-A







RN 365546-41-4 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-4-[(2-propen-1-yloxy) imino]-N-[2-(1H-pyrrol-1-yl)phenyl]- (CA INDEX NAME)




RN 365546-42-5 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 4-[[(3,4-dichlorophenyl)methoxy] imino]-N-(2-furanylmethyl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl) carbonyl]- (CA INDEX NAME)






RN 365546-46-9 CAPLUS
 CN 2-Pyrrolidinecarboxamide, N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S,4E)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 365546-47-0 CAPLUS
 CN 2-Pyrrolidinecarboxamide, N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S,4Z)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 365546-48-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-, (2S,4E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 365546-49-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidines as inhibitors of Bax function)
RN 365546-49-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-, (2S,4Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 13726-69-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolidines as inhibitors of Bax function)
RN 13726-69-7 CAPLUS
CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 84348-37-8P, (2S)-1-(tert-Butoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic acid 102195-80-2P 364078-01-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrolidines as inhibitors of Bax function)
 RN 84348-37-8 CAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) ester,
 (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 102195-80-2 CAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 364078-01-3 CAPLUS
 CN 2-Pyrrolidinecarboxamide, N-[2-(acetyloxy)ethyl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2001:730700 CAPLUS Full-text
 DN 135:288686
 TI Synthesis of substituted N-acyl/sulfonyl pyrrolidine derivatives as bax inhibitors
 IN Halazy, Serge; Schwarz, Matthias; Quattropani, Anna; Thomas, Russel; Baxter, Anthony; Scheer, Alexander
 PA Applied Research Systems ARS Holding N.V., Neth. Antilles
 SO PCT Int. Appl., 219 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072705	A1	20011004	WO 2001-EP3171	20010320
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2401242	A1	20011004	CA 2001-2401242	20010320
	EP 1268419	A1	20030102	EP 2001-929439	20010320
	EP 1268419	B1	20060621		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR	2001009900	A	20030603	BR 2001-9900	20010320
HU	2003000994	A2	20030828	HU 2003-994	20010320
JP	2003528854	T	20030930	JP 2001-570618	20010320
NZ	521060	A	20040528	NZ 2001-521060	20010320
EE	200200555	A	20040615	EE 2002-555	20010320
AU	2001256209	B2	20060216	AU 2001-256209	20010320
AT	330940	T	20060715	AT 2001-929439	20010320
ES	2261404	T3	20061116	ES 2001-929439	20010320
CN	1296354	C	20070124	CN 2001-807176	20010320
ZA	2002006799	A	20030826	ZA 2002-6799	20020826
IN	2002MN01184	A	20040605	IN 2002-MN1184	20020828
BG	107132	A	20030430	BG 2002-107132	20020923
MX	2002009382	A	20030128	MX 2002-9382	20020925
NO	323969	B1	20070723	NO 2002-4598	20020925

US	20030212012	A1	20031113	US	2003-239912	20030210
US	7211601	B2	20070501			
HK	1054031	A1	20070504	HK	2003-106333	20030905
IN	2005MN01049	A	20060519	IN	2005-MN1049	20050927
US	20080167318	A1	20080710	US	2007-783341	20070409
PRAI	EP 2000-106034	A	20000327			
	WO 2001-EP3171	W	20010320			
	IN 2002-MN1184	A3	20020828			
	US 2003-239912	A3	20030210			
OS	MARPAT 135:288686					
GI						




AB Title compds. I [X = CR₆R₇, NOR₆, NNR₆R₇; A = C:O, C:OO, C:NH, C:ONH, C:SNH, S:O, S:ONH, CH; B = amide or II; Q = NR₁₀, O, S; n = 0 - 2; Y, Z, E form together with the 2 C to which they are attached a 5-6 membered (hetero)aryl; R₁ = alk(en/yn)yl, (hetero)aryl, cycloalkyl, acyl, etc.; R₂₋₅ = H, halo, alkyl, alkoxy; R₆₋₇ = H, alk(en/yn)yl, (thio)alkoxy, halogen, CN, NO₂, acyl, alkoxycarbonyl, aminocarbonyl, (hetero)cycloalkyl, etc.; R₁₁ = H, alk(en/yn)yl, OH, SH, etc. with some provisions] were prepared and used as bax inhibitors. Over 400 compds. were disclosed. E.g., (2S)-1-(tert-butoxycarbonyl)-4-(methoxyimino)-2- pyrrolidinecarboxylic acid (preparation given) was condensed with (S)-2-amino-1-phenylethanol (THF, i-BuOCOCl, -25°C - room temperature, 16 h) and the coupled product deprotected (DCM, HCl) to give the pyrrolidine. This intermediate was condensed with 4-(2-methylphenyl)benzoic acid (DMF, ClCOCOCl, Et₃N, room temperature) to give a mixture of oxime ethers which were separated by chromatog. to give III. III had IC₅₀ = 0.07 μM for the oxytocin receptor. I are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea.

IT 364071-39-6P 364071-41-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug; synthesis of substituted N-acyl/sulfonyl pyrrolidine derivs. as


bax inhibitors)
RN 364071-39-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S,4E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 364071-41-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S,4Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 364071-15-8P 364071-16-9P 364071-17-0P
364071-19-2P 364071-31-8P 364071-33-0P
364071-35-2P 364071-37-4P 364071-43-2P
364071-45-4P 364071-47-6P 364071-49-8P
364071-51-2P 364071-53-4P 364071-55-6P
364071-57-8P 364071-71-6P 364071-73-8P
364071-79-4P 364071-81-8P 364071-83-0P
364071-91-0P 364071-97-6P 364072-01-5P
364072-03-7P 364072-05-9P 364072-11-7P
364072-17-3P 364072-33-3P 364072-37-7P
364072-53-7P 364072-54-8P 364072-61-7P
364072-63-9P 364072-67-3P 364072-71-9P
364072-73-1P 364072-87-7P 364072-90-2P
364073-25-6P 364073-28-9P 364073-30-3P
364073-46-1P 364073-58-5P 364073-63-2P
364073-70-1P 364073-73-4P 364073-79-0P
364074-08-8P 364074-15-7P 364074-16-8P
364074-19-1P 364074-20-4P 364074-22-6P
364074-23-7P 364074-28-2P 364074-29-3P

364074-34-0P 364074-35-1P 364074-41-9P
364074-43-1P 364074-45-3P 364074-55-5P
364074-83-9P 364074-89-5P 364074-94-2P
364074-98-6P 364075-03-6P 364075-04-7P
364075-13-8P 364075-17-2P 364075-21-8P
364075-27-4P 364075-30-9P 364075-43-4P
364075-45-6P 364075-51-4P 364075-55-8P
364075-59-2P 364075-86-5P 364075-96-7P
364076-10-8P 364076-14-2P 364076-16-4P
364076-18-6P 364076-20-0P 364076-22-2P
364076-25-5P 364076-27-7P 364076-28-8P
364076-30-2P 364076-31-3P 364076-32-4P
364076-33-5P 364076-35-7P 364076-37-9P
364076-38-0P 364076-40-4P 364076-41-5P
364076-42-6P 364076-43-7P 364076-44-8P
364076-46-0P 364076-47-1P 364076-49-3P
364076-52-3P 364076-53-9P 364076-54-0P
364076-55-1P 364076-57-3P 364076-58-4P
364076-59-5P 364076-61-9P 364076-62-0P
364076-63-1P 364076-64-2P 364076-66-4P
364076-68-6P 364076-69-7P 364076-70-0P
364076-72-2P 364076-74-4P 364076-75-5P
364076-76-6P 364076-77-7P 364076-78-8P
364076-80-2P 364076-81-3P 364076-82-4P
364076-89-1P 364076-92-6P 364076-94-8P
364076-99-3P 364077-00-9P 364077-01-0P
364077-02-1P 364077-03-2P 364077-04-3P
364077-05-4P 364077-06-5P 364077-07-6P
364077-08-7P 364077-09-8P 364077-10-1P
364077-11-2P 364077-12-3P 364077-13-4P
364077-14-5P 364077-15-6P 364077-16-7P
364077-17-8P 364077-18-9P 364077-19-0P
364077-20-3P 364077-21-4P 364077-22-5P
364077-23-6P 364077-24-7P 364077-25-8P
364077-26-9P 364077-27-0P 364077-28-1P
364077-29-2P 364077-30-5P 364077-31-6P
364077-32-7P 364077-33-8P 364077-34-9P
364077-35-0P 364077-36-1P 364077-37-2P
364077-38-3P 364077-39-4P 364077-40-7P
364077-41-8P 364077-42-9P 364077-43-0P
364077-44-1P 364077-45-2P 364077-46-3P
364077-47-4P 364077-48-5P 364077-49-6P
364077-50-9P 364077-51-0P 364077-52-1P
364077-53-2P 364077-54-3P 364077-55-4P
364077-56-5P 364077-57-6P 364077-58-7P
364077-59-8P 364077-60-1P 364077-61-2P
364077-62-3P 364077-63-4P 364077-64-5P
364077-65-6P 364077-66-7P 364077-67-8P
364077-68-9P 364077-69-0P 364077-70-3P
364077-71-4P 364077-72-5P 364077-73-6P
364077-74-7P 364077-75-8P 364077-76-9P
364077-77-0P 364077-78-1P 364077-79-2P
364077-80-5P 364077-81-6P 364077-82-7P
364077-83-8P 365456-63-9P 365456-67-3P
365456-73-1P 365456-76-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of substituted N-acyl/sulfonyl pyrrolidine derivs. as bax inhibitors)

RN 364071-15-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-methoxyethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-16-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S,4E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 364071-17-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S,4Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 364071-19-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-(diethylamino)ethyl]-4-[(4-methoxyphenyl)methoxy]imino-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-31-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-4-(methoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S,4E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 364071-33-0 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-4-(methoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S,4Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 364071-35-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-benzoyl-N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364071-37-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxyethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364071-43-2 CAPLUS
CN 3-Pyrrolidinone, 5-(1H-benzimidazol-2-yl)-1-([1,1'-biphenyl]-4-ylcarbonyl)-3-(O-methyloxime), (3E,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 364071-45-4 CAPLUS

CN 3-Pyrrolidinone, 5-(1H-benzimidazol-2-yl)-1-([1,1'-biphenyl]-4-ylcarbonyl)-, 3-(O-methyloxime), (3Z,5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 364071-47-6 CAPLUS

CN 3-Pyrrolidinone, 5-(1H-benzimidazol-2-yl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364071-49-8 CAPLUS


CN 3-Pyrrolidinone, 5-(1-methyl-1H-benzimidazol-2-yl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364071-51-2 CAPLUS
CN 3-Pyrrolidinone, 5-(7-hydroxy-1H-benzimidazol-2-yl)-1-[(2'-methyl[1,1'biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364071-53-4 CAPLUS
CN 3-Pyrrolidinone, 5-(1,4-dihydro-2-quinazolinyl)-1-[(2'-methyl[1,1'biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364071-55-6 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-(1-methyl-1H-benzimidazol-2-yl)-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364071-57-8 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(hydroxyimino)-N-(2-hydroxy-2-phenylethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364071-71-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-4-[(2-propen-1-yloxy)imino]-N-[2-(1H-pyrrol-1-yl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364071-73-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[(3,4-dichlorophenyl)methoxy]imino]-N-(2-furanyl methyl)-1-[2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-79-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-N-(2-furanyl methyl)-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-81-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-(diethylamino)ethyl]-1-(4-phenoxybenzoyl)-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-83-0 CAPLUS

CN Benzonitrile, 4-[(2S)-2-[[4-(3,4-dichlorophenyl)-1-piperazinyl]carbonyl]-4-[(phenylmethoxy)imino]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-91-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-(diethylamino)ethyl]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364071-97-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-N-(9-ethyl-9H-carbazol-3-yl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-01-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[(1,1-dimethylethoxy)imino]-N-(2-methoxyethyl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-03-7 CAPLUS

CN 3-Pyrrolidinone, 5-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]-1-benzoyl-, 3-[O-[(3,4-dichlorophenyl)methyl]oxime], (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-05-9 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[[(2S)-4-(ethoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-2-pyrrolidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-11-7 CAPLUS

CN 3-Pyrrolidinone, 5-[{4-(3,4-dichlorophenyl)-1-piperazinyl}carbonyl]-1-[{(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl}-, 3-[O-(phenylmethyl)oxime], (5S)-(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-17-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(4,6-dimethoxy-2-pyrimidinyl)-1-[{(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl}-4-[{(phenylmethoxy)imino]-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364072-33-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1-(4-cyanobenzoyl)-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364072-37-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-[(3,4-dichlorophenyl)methoxy]imino]-N-[2-(1H-pyrrol-1-yl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364072-53-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-2,1,3-benzothiadiazol-4-yl-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364072-54-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-61-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-N-2-propen-1-yl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-63-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-N-(2-thienylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-67-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-furanyl methyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-71-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-furanyl methyl)-4-(methoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364072-73-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-N-methyl-N-(phenylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364072-87-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-(diethylamino)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364072-90-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(3,4-dimethoxyphenyl)methyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364073-25-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-[(3,4-dichlorophenyl)methoxy]imino]-N-[2-(diethylamino)ethyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364073-28-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364073-30-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-N-(phenylmethyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364073-46-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-benzoyl-4-[(3,4-dichlorophenyl)methoxy]imino-N-6-quinolinyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364073-58-5 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-4-[(3,4-dichlorophenyl)methoxy]imino-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364073-63-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364073-70-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-benzoyl-N-[2-(diethylamino)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364073-73-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-2,1,3-benzothiadiazol-4-yl-1-(4-cyanobenzoyl)-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364073-79-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-N-[2-(diethylamino)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-08-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-benzoyl-N-(2-furanyl methyl)-4-[(4-methoxyphenyl)methoxy]imino-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-15-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[(1,1-dimethylethoxy)imino]-1-[(2-ethoxy-1-naphthalenyl)carbonyl]-N-(9-ethyl-9H-carbazol-3-yl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-16-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-benzoyl-N-[2-(diethylamino)ethyl]-4-(ethoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-19-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-4-[(3,4-dichlorophenyl)methoxy]imino-N-(1-naphthalenylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-20-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-2,1,3-benzothiadiazol-4-yl-1-benzoyl-4-[(4-methoxyphenyl)methoxy]imino-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-22-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(ethoxyimino)-N-(9-ethyl-9H-carbazol-3-yl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-23-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-benzoyl-4-(ethoxyimino)-N-(9-ethyl-9H-carbazol-3-yl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-28-2 CAPLUS

CN 3-Pyrrolidinone, 1-benzoyl-5-[(4-(3,4-dichlorophenyl)-1-piperazinyl)carbonyl]-, 3-(O-ethyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-29-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-34-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-35-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[[4-methoxyphenyl)methoxy]imino]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-41-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-1-(4-phenoxybenzoyl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-43-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-1-[(2-oxo-6-pentoxy-2H-pyran-3-yl)carbonyl]-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-45-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(ethoxyimino)-N-(9-ethyl-9H-carbazol-3-yl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-55-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(phenylmethoxy)imino]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-83-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(ethoxyimino)-N-(9-ethyl-9H-carbazol-3-yl)-1-(4-phenoxybenzoyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-89-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(3,4-dimethoxyphenyl)methyl]-4-[(1,1-dimethylethoxy)imino]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-94-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(4,6-dimethoxy-2-pyrimidinyl)-4-(ethoxyimino)-1-(4-phenoxybenzoyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364074-98-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(9-ethyl-9H-carbazol-3-yl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-03-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-04-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(4-methoxyphenyl)methoxy]imino]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-13-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(9-ethyl-9H-carbazol-3-yl)-4-(methoxyimino)-1-(4-phenoxybenzoyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-17-2 CAPLUS

CN 3-Pyrrolidinone, 5-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, 3-[O-(1,1-dimethylethyl)oxime], (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-21-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-benzoyl-4-[(2-propen-1-yloxy)imino]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-27-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2-ethoxy-1-naphthalenyl)carbonyl]-N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-30-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-43-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-cyclopropyl-4-[(1,1-dimethylethoxy)imino]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-45-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[[4-methoxyphenyl)methoxy]imino]-1-(4-phenoxybenzoyl)-N-[4-(1H-pyrrol-1-yl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-51-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(3,4-dimethoxyphenyl)methyl]-4-(ethoxyimino)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-55-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(phenylmethoxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-59-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-(4-cyanobenzoyl)-N-(2-methoxyethyl)-4-[(2-propen-1-yloxy)imino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-86-5 CAPLUS

CN 3-Pyrrolidinone, 1-benzoyl-5-(4-morpholinylcarbonyl)-3-[O-[(3,4-dichlorophenyl)methyl]oxime], (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364075-96-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-[(3,4-dichlorophenyl)methoxy]imino]-1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-10-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2-oxo-6-pentyl-2H-pyran-3-yl)carbonyl]-4-[(2-propen-1-yloxy)imino]-N-6-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-14-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-16-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-3-ylcarbonyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-18-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((4-benzoylbenzoyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-20-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-(3-phenoxybenzoyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-22-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-(2-phenoxybenzoyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-25-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364076-27-7 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-(2-hydroxyethyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-28-8 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(2-hydroxyethyl)-4-(methoxyimino)-N-methyl-1-[2'-methyl[1,1'-biphenyl]-4-yl]carbonyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364076-30-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(trans-4-hydroxycyclohexyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-31-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(1R,2R)-2-(hydroxymethyl)cyclohexyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-32-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxy-3-phenoxypropyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-33-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-3-phenoxypropyl)-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-35-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-37-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(1-hydroxycyclohexyl)methyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-38-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1-hydroxycyclohexyl)methyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-40-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-41-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-42-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-43-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(2-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-44-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2,3-dihydroxypropyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364076-46-0 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-47-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-49-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxypropyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-52-8 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-hydroxy-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-53-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-54-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-55-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-1-[4-(2-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-57-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-(acetylamino)phenoxy]-2-hydroxypropyl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364076-58-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-(acetylamino)phenoxy]-2-hydroxypropyl]-4-(methoxyimino)-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-59-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-(acetylamino)phenoxy]-2-hydroxypropyl]-4-

(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-61-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-62-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-63-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-64-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2R)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[4-(2-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-66-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(3-hydroxypropyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-68-6 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[(4-hydroxy-4-phenyl-1-piperidinyl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-69-7 CAPLUS
CN 3-Pyrrolidinone, 5-[(4-hydroxy-4-phenyl-1-piperidinyl)carbonyl]-1-[4-(4-pyridinyl)benzoyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364076-70-0 CAPLUS
CN 3-Pyrrolidinone, 5-[(4-hydroxy-4-phenyl-1-piperidinyl)carbonyl]-1-[4-(3-pyridinyl)benzoyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-72-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(1S,2S)-2-hydroxycyclohexyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-74-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-((2-hydroxyethyl)-4-(methoxyimino)-N-(phenylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-75-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxyethyl)-4-(methoxyimino)-N-(phenylmethyl)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-76-6 CAPLUS

CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[(3-hydroxy-1-piperidinyl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-77-7 CAPLUS

CN 3-Pyrrolidinone, 5-[(3-hydroxy-1-piperidinyl)carbonyl]-1-[4-(4-pyridinyl)benzoyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364076-78-8 CAPLUS


CN 3-Pyrrolidinone, 5-[(3-hydroxy-1-piperidinyl)carbonyl]-1-[4-(3-pyridinyl)benzoyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-80-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-81-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-4-(methoxyimino)-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-82-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-4-(methoxyimino)-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-89-1 CAPLUS
CN 3-Pyrrolidinone, 1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[(4-hydroxy-1-piperidinyl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364076-92-6 CAPLUS
CN β-Alaninamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364076-94-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-(4-hydroxybutyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364076-99-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-00-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(1R,2S)-2-(hydroxymethyl)cyclohexyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-01-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-02-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1S,2R,3S,4R)-3-(aminocarbonyl)bicyclo[2.2.1]hept-5-en-2-yl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364077-03-2 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[(1S,2S,3R,4R)-3-(aminocarbonyl)bicyclo[2.2.1]hept-5-en-2-yl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-04-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-05-4 CAPLUS
CN Propanoic acid, 3-[[[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]carbonyl]amino]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-06-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R,2S)-2-(aminocarbonyl)cyclohexyl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-07-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-(2-hydroxy-1-methylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-08-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-09-8 CAPLUS
CN Butanoic acid, 4-[[[(2S)-1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-10-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-1-[(2' -methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-11-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(2-naphthalenyl)ethyl]-1-[(2' -methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-12-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-1-methylethyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-13-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-14-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-15-6 CAPLUS

CN 3-Pyrrolidinone, 5-[(4-hydroxy-1-piperidinyl)carbonyl]-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-16-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1S,2S,3R,4R)-3-(aminocarbonyl)bicyclo[2.2.1]hept-5-en-2-yl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-17-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-1-[(2'-methoxy[1,1'-

biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-18-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxypropyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-19-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2,3-dihydroxypropyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-20-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(3-hydroxypropyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-21-4 CAPLUS
CN Glycinamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-22-5 CAPLUS
CN Glycinamide, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-23-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-24-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(1S,2R,3S,4R)-3-(hydroxymethyl)bicyclo[2.2.1]hept-2-yl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364077-25-8 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[(1R,2S,3R,4S)-3-(hydroxymethyl)bicyclo[2.2.1]hept-2-yl]-1-((2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-26-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(trans-4-hydroxycyclohexyl)-1-[(2' -
methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX
NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-27-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R,2R)-2-(hydroxymethyl)cyclohexyl]-1-[(2' -
methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX
NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-28-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-3-phenoxypropyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-29-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-30-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-31-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)ethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-32-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)ethyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-33-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-1-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-34-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-([1,1'-biphenyl]-4-ylcarbonyl)-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-35-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-36-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2'-cyano[1,1'-biphenyl]-4-yl)carbonyl]-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-37-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(3',4'-dichloro[1,1'-biphenyl]-4-yl)carbonyl]-N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364077-38-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-39-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-(2-hydroxy-2-phenylethyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-40-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-
(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-41-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2'-cyano[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-42-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(3',4'-dichloro[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-43-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX
NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-44-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX
NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-45-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3',4'-dichloro[1,1'-biphenyl]-4-yl)carbonyl]-
N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX
NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-46-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-47-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-48-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-(methoxyimino)-, (2S)- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-49-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-
N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-(methoxyimino)-, (2S)- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-50-9 CAPLUS
CN Glycinamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-4-
(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-51-0 CAPLUS

CN Glycinamide, 1-[2',3'-dimethyl[1,1'-biphenyl]-4-yl]carbonyl]-4-(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-52-1 CAPLUS

CN β -Alaninamide, 1-[2',6'-dimethyl[1,1'-biphenyl]-4-yl]carbonyl]-4-(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-53-2 CAPLUS

CN β -Alaninamide, 1-[2',3'-dimethyl[1,1'-biphenyl]-4-yl]carbonyl]-4-

(methoxyimino)-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-54-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-55-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-56-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2'-cyano[1,1'-biphenyl]-4-yl)carbonyl]-N-[(1R,2R)-2-(hydroxymethyl)cyclohexyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-57-6 CAPLUS

CN 3-Pyrrolidinone, 5-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-58-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-59-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-(4-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-60-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-61-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[2-(3-hydroxyphenyl)ethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-62-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-N-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364077-63-4 CAPLUS

CN Phenylalanine, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-64-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1R,2S)-2-(aminocarbonyl)cyclohexyl]-1-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-65-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1R,2S)-2-(aminocarbonyl)cyclohexyl]-1-[(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-66-7 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[(2S)-2-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-4-(methoxyimino)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-67-8 CAPLUS

CN 3-Pyrrolidinone, 1-[(3',4'-dichloro[1,1'-biphenyl]-4-yl)carbonyl]-5-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-68-9 CAPLUS
CN 3-Pyrrolidinone, 1-[{(2',6'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl}-5-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-69-0 CAPLUS
CN 3-Pyrrolidinone, 1-[{(2',3'-dimethyl[1,1'-biphenyl]-4-yl)carbonyl}-5-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-70-3 CAPLUS
CN 3-Pyrrolidinone, 1-[{(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl}-5-[[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-71-4 CAPLUS

CN 3-Pyrrolidinone, 1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-5-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-, 3-(O-methyloxime), (5S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-72-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-73-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-N-methyl-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-74-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-N,N-dimethyl-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-75-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(3R)-3-hydroxy-3-phenylpropyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-76-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(3S)-3-hydroxy-3-phenylpropyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-77-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(3R)-3-hydroxy-3-phenylpropyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 364077-78-1 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-N-[(3S)-3-hydroxy-3-phenylpropyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-79-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 364077-80-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2'-chloro[1,1'-biphenyl]-4-yl)carbonyl]-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 364077-81-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2-hydroxyphenyl)-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-82-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-(hydroxymethyl)phenyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 364077-83-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-N-(2-phenylethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 365456-63-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-((1,1'-biphenyl)-4-ylcarbonyl)-4-(methoxyimino)-N-[2-(phenylamino)ethyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 365456-67-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-N-[2-(phenylamino)ethyl]-1-[4-(4-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 365456-73-1 CAPLUS


CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-N-[2-(phenylamino)ethyl]-1-[4-(3-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 365456-76-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-(methoxyimino)-N-[2-(phenylamino)ethyl]-1-[4-(2-pyridinyl)benzoyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 84348-37-8P 102195-80-2P 364077-84-9P
364078-01-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; synthesis of substituted N-acyl/sulfonyl pyrrolidine
derivs. as bax inhibitors)
RN 84348-37-8 CAPLUS
CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) ester,
(2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 102195-80-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 364077-84-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 364078-01-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-(acetyloxy)ethyl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




IT 51-35-4 13726-69-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; synthesis of substituted N-acyl/sulfonyl pyrrolidine derivs.
as bax inhibitors)

RN 51-35-4 CAPLUS

CN L-Proline, 4-hydroxy-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 13726-69-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) ester,
(2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1984:138816 CAPLUS Full-text

DN 100:138816

OREF 100:21171a,21174a

TI Studies on tomaymycin. III. Syntheses and antitumor activity of tomaymycin analogs

AU Tozuka, Zenzaburo; Yazawa, Hisatoyo; Murata, Masayoshi; Takaya, Takao

CS Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, Japan


SO Journal of Antibiotics (1983), 36(12), 1699-708

CODEN: JANTAJ; ISSN: 0021-8820

DT Journal

LA English

GI



AB Analogs I-III [X = CH₂, CH₂CH₂, S, CHO, CO, CHO₂C(CH₂)₁₄Me, CO, C:NOMe, C:CHCN, C:CHMe; R = OMe, NEt₂, SET, SCH₂Ph] of tomaymycin (II, X = C:CHMe, R = OMe) were prepared. Most of them were inactive against leukemia P388 in mice and the activity of the others was less than that of tomaymycin. Only the O-Me derivative of tomaymycin had antileukemic activity comparable to that of the parent.


IT 64154-80-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)

RN 64154-80-9 CAPLUS

CN L-Proline, 4-hydroxy-1-[5-methoxy-2-nitro-4-(phenylmethoxy)benzoyl]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 89229-32-3P 89229-33-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and deblocking of)

RN 89229-32-3 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[5-methoxy-2-nitro-4-[(4-nitrophenyl)methoxy]benzoyl]-, diphenylmethyl ester, (E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 89229-33-4 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[5-methoxy-2-nitro-4-[(4-nitrophenyl)methoxy]benzoyl]-, diphenylmethyl ester, (Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 89300-03-8P 89300-04-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)

RN 89300-03-8 CAPLUS

CN 2-Pyrrolidinecarboxaldehyde, 4-(methoxyimino)-1-[5-methoxy-2-nitro-4-[(4-nitrophenyl)methoxy]benzoyl]-, [S-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 89300-04-9 CAPLUS

CN 2-Pyrrolidinecarboxaldehyde, 4-(methoxyimino)-1-[5-methoxy-2-nitro-4-[(4-nitrophenyl)methoxy]benzoyl]-, [S-(Z)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 89229-36-7P 89229-37-8P 89229-40-3P

89229-41-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 89229-36-7 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[5-methoxy-2-nitro-4-[(4-nitrophenyl)methoxy]benzoyl]-, (E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 89229-37-8 CAPLUS

CN L-Proline, 4-(methoxyimino)-1-[5-methoxy-2-nitro-4-[(4-nitrophenyl)methoxy]benzoyl]-, (Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 89229-40-3 CAPLUS

CN L-Proline, 1-[5-methoxy-2-nitro-4-(phenylmethoxy)benzoyl]-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 89229-41-4 CAPLUS

CN L-Proline, 1-[5-methoxy-2-nitro-4-(phenylmethoxy)benzoyl]-4-[(1-oxohexadecyl)oxy]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 81307-07-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with methoxyamine)

RN 81307-07-5 CAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl)
2-(diphenylmethyl) ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log hold

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

FULL ESTIMATED COST

59.15	442.21
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

CA SUBSCRIBER PRICE

-8.20	-8.20
-------	-------

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 16:17:55 ON 08 JUN 2009